var title_f32_30_33248="Ganciclovir: Drug information";
var content_f32_30_33248=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ganciclovir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/5/6228?source=see_link\">",
"       Ganciclovir (ophthalmic): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/3/24630?source=see_link\">",
"       Ganciclovir (systemic): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8485 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-12D3B89698-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33248=[""].join("\n");
var outline_f32_30_33248=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/5/6228?source=related_link\">",
"      Ganciclovir (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/3/24630?source=related_link\">",
"      Ganciclovir (systemic): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_30_33249="Patient information: Antisocial personality disorder (The Basics)";
var content_f32_30_33249=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?38/28/39361\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/57/12179\">",
"         Patient information: Depression (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/6/24675\">",
"         Patient information: Medicines for depression (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/21/44371\">",
"         Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/6/13413\">",
"         Patient information: Depression in adolescents (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/41/20116\">",
"         Patient information: Depression in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Antisocial personality disorder (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/antisocial-personality-disorder-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H11874297\">",
"      <span class=\"h1\">",
"       What is antisocial personality disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;People with antisocial personality disorder have many behavior problems, such as lying, cheating, fighting, and breaking the law. These problems affect many parts of their lives (for example, school, work, and relationships). The disorder is more common in men than in women.",
"     </p>",
"     <p>",
"      People with this condition often have trouble getting along with others and keeping a job. They do not feel sorry about how their actions might hurt other people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11874312\">",
"      <span class=\"h1\">",
"       What are the symptoms of antisocial personality disorder?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In people who are younger than 15 years old, symptoms include: &nbsp;",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Breaking rules",
"       </li>",
"       <li>",
"        Destroying things",
"       </li>",
"       <li>",
"        Lying",
"       </li>",
"       <li>",
"        Stealing",
"       </li>",
"       <li>",
"        Fighting",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      About half of teens with these behaviors learn to be more responsible when they are adults.",
"     </p>",
"     <p>",
"      Adults with antisocial personality disorder continue to have similar symptoms, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Breaking laws",
"       </li>",
"       <li>",
"        Getting arrested often",
"       </li>",
"       <li>",
"        Using a fake name (called an &ldquo;alias&rdquo;)",
"       </li>",
"       <li>",
"        Taking advantage of other people",
"       </li>",
"       <li>",
"        Hurting other people",
"       </li>",
"       <li>",
"        Bragging about their bad behavior",
"       </li>",
"       <li>",
"        Not feeling sorry about their bad behavior",
"       </li>",
"       <li>",
"        Being unable to keep a job",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who have a few of these symptoms for short periods of time do not have antisocial personality disorder. To have the disorder, people must have multiple symptoms that last for years and affect all parts of their lives.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11874327\">",
"      <span class=\"h1\">",
"       How is antisocial personality disorder treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are no good ways to treat antisocial personality disorder. But people with this disorder often have other problems, such as depression and alcohol or drug abuse. Seeing a counselor (such as a psychiatrist, psychologist, nurse, or social worker)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      taking medicines can help treat those problems.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H11874342\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=see_link\">",
"       Patient information: Depression (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=see_link\">",
"       Patient information: Medicines for depression (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=see_link\">",
"       Patient information: Depression in adolescents (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=see_link\">",
"       Patient information: Depression in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/21/44371?source=see_link\">",
"       Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?32/30/33249?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83080 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-42B8F45CE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33249=[""].join("\n");
var outline_f32_30_33249=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11874297\">",
"      What is antisocial personality disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11874312\">",
"      What are the symptoms of antisocial personality disorder?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11874327\">",
"      How is antisocial personality disorder treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11874342\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/21/44371?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/57/12179?source=related_link\">",
"      Patient information: Depression (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/6/13413?source=related_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/41/20116?source=related_link\">",
"      Patient information: Depression in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/6/24675?source=related_link\">",
"      Patient information: Medicines for depression (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_30_33250="Patient information: Anaphylaxis (The Basics)";
var content_f32_30_33250=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15336\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"         Hives",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?34/27/35250\">",
"         Patient information: Food allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/51/15155\">",
"         Patient information: Insect bites and stings (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/35/17971\">",
"         Patient information: Peanut allergy (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/37/22098\">",
"         Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?14/57/15250\">",
"         Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?40/14/41186\">",
"         Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/30/28134\">",
"         Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Anaphylaxis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/anaphylaxis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H40065098\">",
"      <span class=\"h1\">",
"       What is anaphylaxis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anaphylaxis is the term doctors use to describe a serious allergic reaction. It can happen very quickly and can cause death. Anaphylaxis can happen after a person:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Eats a food he or she is allergic to",
"       </li>",
"       <li>",
"        Takes a medicine he or she is allergic to",
"       </li>",
"       <li>",
"        Is stung by an insect he or she is allergic to",
"       </li>",
"       <li>",
"        Touches something made out of latex if he or she is allergic to latex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other triggers can also cause anaphylaxis.",
"     </p>",
"     <p>",
"      You might know if you are allergic to something. But you can also have anaphylaxis even if you don&rsquo;t know you have an allergy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40065105\">",
"      <span class=\"h1\">",
"       What are the symptoms of anaphylaxis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Anaphylaxis can involve one or more parts of the body. The most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Hives &ndash; raised, red patches of skin that are very itchy (",
"        <a class=\"graphic graphic_picture graphicRef79242 \" href=\"UTD.htm?7/41/7824\">",
"         picture 1",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Angioedema &ndash; a condition that causes puffiness, usually of the face, eyelids, ears, mouth, hands, or feet",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Redness or itching of the skin (without hives)",
"       </li>",
"       <li>",
"        Swelling or itching of the eyes",
"       </li>",
"       <li>",
"        Runny nose or swelling of the tongue",
"       </li>",
"       <li>",
"        Trouble breathing, wheezing, or a change in your voice",
"       </li>",
"       <li>",
"        Throwing up or having diarrhea",
"       </li>",
"       <li>",
"        Feeling dizzy or passing out",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      With anaphylaxis, you can get very sick, very quickly. Your symptoms can also change. You may first get hives on your skin. Soon after that, you may throw up or have trouble breathing. Each time you have anaphylaxis, you can have different symptoms. Symptoms also differ from person to person.",
"     </p>",
"     <p>",
"      The symptoms you have with anaphylaxis can be worse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have asthma",
"       </li>",
"       <li>",
"        Have other health problems such as lung or heart disease",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40065112\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you think you have anaphylaxis,",
"      <strong>",
"       call 9-1-1 for an ambulance",
"      </strong>",
"      . Do not try to get yourself to the hospital. Anaphylaxis can lead to death.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40065119\">",
"      <span class=\"h1\">",
"       How is anaphylaxis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;At the hospital, the staff will give you treatments to stop the anaphylaxis and reduce your symptoms. The staff will also watch you to make sure your symptoms do not get worse.",
"     </p>",
"     <p>",
"      People who have had anaphylaxis before often get a prescription for a device called an auto-injector (for example, the EpiPen). This device carries one or two shots of a medicine called epinephrine. This medicine can help stop anaphylaxis. The auto-injector makes it easy for you to give yourself the shot. If you have an auto-injector, you should keep it with you at all times. Use it right away any time you think you are having anaphylaxis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40065126\">",
"      <span class=\"h1\">",
"       Is there anything I can do to prevent anaphylaxis again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have had anaphylaxis, you should talk with your doctor or nurse. If needed, your doctor can do tests to find out what you are allergic to.",
"     </p>",
"     <p>",
"      Your doctor can help you make a plan to prevent future anaphylaxis. As part of your plan, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Learn about the symptoms of anaphylaxis so you will know when to get help",
"       </li>",
"       <li>",
"        Have an epinephrine auto-injector with you at all times",
"       </li>",
"       <li>",
"        Avoid foods, medicines, or insects you are allergic to",
"       </li>",
"       <li>",
"        Wear a medical bracelet to let others know about your allergy",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40065133\">",
"      <span class=\"h1\">",
"       What will my life be like?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people who have had anaphylaxis are able to live normal lives. But you might need to make some changes in your life. You will need to avoid the things that can cause you to have anaphylaxis. You may need to carry medicine with you in case you have an allergic reaction.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40065140\">",
"      <span class=\"h1\">",
"       What if I have an allergy to penicillin?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Penicillin is a common medicine doctors use to treat infections. Some people are allergic to penicillin. They can have anaphylaxis if they take it. These people should not take any type of penicillin medicine.",
"     </p>",
"     <p>",
"      Other people who think they have a penicillin allergy might be able to take it without a problem. If you have been told you are allergic to penicillin, talk to your doctor. Your doctor can do tests to find out more about your penicillin allergy. You may be able to take penicillin in the future if you need it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H40065147\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=see_link\">",
"       Patient information: Food allergy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=see_link\">",
"       Patient information: Insect bites and stings (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=see_link\">",
"       Patient information: Peanut allergy (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=see_link\">",
"       Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=see_link\">",
"       Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=see_link\">",
"       Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=see_link\">",
"       Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?32/30/33250?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15336 Version 5.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-0D12DA5E94-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33250=[""].join("\n");
var outline_f32_30_33250=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40065098\">",
"      What is anaphylaxis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40065105\">",
"      What are the symptoms of anaphylaxis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40065112\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40065119\">",
"      How is anaphylaxis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40065126\">",
"      Is there anything I can do to prevent anaphylaxis again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40065133\">",
"      What will my life be like?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40065140\">",
"      What if I have an allergy to penicillin?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40065147\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/41/7824\">",
"      Hives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=related_link\">",
"      Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/27/35250?source=related_link\">",
"      Patient information: Food allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/51/15155?source=related_link\">",
"      Patient information: Insect bites and stings (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/35/17971?source=related_link\">",
"      Patient information: Peanut allergy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_30_33251="Difenoxin and atropine: Drug information";
var content_f32_30_33251=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Difenoxin and atropine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/8/36996?source=see_link\">",
"    see \"Difenoxin and atropine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F159875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Motofen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F159887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiarrheal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F159877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diarrhea:",
"     </b>",
"     Oral: Initial: 2 tablets (each tablet contains difenoxin hydrochloride 1 mg and atropine sulfate 0.025 mg), then 1 tablet after each loose stool; 1 tablet every 3-4 hours, up to 8 tablets in a 24-hour period; if no improvement after 48 hours, continued administration is not indicated",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F159878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment provided in manufacturer&rsquo;s labeling. Use with extreme caution in patients with advanced hepatorenal disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment provided in manufacturer&rsquo;s labeling. Use with extreme caution in patients with advanced hepatorenal disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Motofen&reg;: Difenoxin hydrochloride 1 mg and atropine sulfate 0.025 mg [dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F159889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F159885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, lightheadedness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting, dry mouth, epigastric distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis, blurred vision, confusion, constipation, tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to difenoxin, atropine, or any component of the formulation; severe liver disease; jaundice; dehydrated patient; angle-closure glaucoma; children &lt;2 years of age; diarrhea associated with organisms that penetrate the intestinal mucosa (toxigenic",
"     <i>",
"      E. coli",
"     </i>",
"     ,",
"     <i>",
"      Salmonella",
"     </i>",
"     sp,",
"     <i>",
"      Shigella",
"     </i>",
"     ), and pseudomembranous colitis associated with broad spectrum antibiotics",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F159852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dehydration/electrolyte imbalance: In case of severe dehydration or electrolyte imbalance, withhold difenoxin/atropine treatment until corrective therapy has been initiated. Use in conjunction with fluid and electrolyte therapy when appropriate. Inhibiting peristalsis may lead to fluid retention in the intestine aggravating dehydration and electrolyte imbalance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ulcerative colitis: Use with caution in patients with acute ulcerative colitis; may induce toxic megacolon. Discontinue promptly with abdominal distention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;12 years of age; contraindicated in children &lt;2 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage recommendations: Strictly adhere to dosage recommendations.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F159872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F159880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F159866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in nursing infants, breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F159865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Motofen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-0.025 mg (100): $503.75",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F159863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To inactive hydroxylated metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Within 40-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and feces (primarily as conjugates)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8727 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-D9EF6866B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33251=[""].join("\n");
var outline_f32_30_33251=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159875\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159887\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159877\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159878\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796060\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796061\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159860\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159849\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159889\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159861\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159885\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159864\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159852\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299192\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219852\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159872\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159856\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287233\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159880\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159866\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159865\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159863\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8727\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8727|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/8/36996?source=related_link\">",
"      Difenoxin and atropine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_30_33252="Mupirocin: Drug information";
var content_f32_30_33252=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Mupirocin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/63/6132?source=see_link\">",
"    see \"Mupirocin: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=see_link\">",
"    see \"Mupirocin: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F198518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bactroban Cream&reg;;",
"     </li>",
"     <li>",
"      Bactroban Nasal&reg;;",
"     </li>",
"     <li>",
"      Bactroban&reg;;",
"     </li>",
"     <li>",
"      Centany&reg;;",
"     </li>",
"     <li>",
"      Centany&reg; AT",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F198519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bactroban&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F198557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F198521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Impetigo:",
"     </b>",
"     Topical: Ointment: Apply to affected area 3 times/day; re-evaluate after 3-5 days if no clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Secondary skin infections:",
"     </b>",
"     Topical: Cream: Apply to affected area 3 times/day for 10 days; re-evaluate after 3-5 days if no clinical response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elimination of MRSA colonization:",
"     </b>",
"     Intranasal: Approximately one-half of the ointment from the single-use tube should be applied into one nostril and the other half into the other nostril twice daily for 5 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F198538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=see_link\">",
"      see \"Mupirocin: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Eradication of nasal MRSA:",
"     </b>",
"     Intranasal: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Impetigo:",
"     </b>",
"     Topical: Ointment: Children &ge;2 months: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Secondary skin infections:",
"     </b>",
"     Topical: Cream: Children &ge;3 months: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F198522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F198500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as calcium [strength expressed as base]: 2% (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bactroban Cream&reg;: 2% (15 g, 30 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 2% (22 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bactroban&reg;: 2% (22 g) [contains polyethylene glycol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Centany&reg;: 2% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Centany&reg; AT: 2% (1s) [kit includes Centany&reg; ointment (30 g),12 gauze pads, and 24 cloth tape strips]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, intranasal, as calcium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bactroban Nasal&reg;: 2% (1 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F198487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal ointment: After application into nostrils, press sides of nose together and gently massage to spread ointment throughout the insides of the nostrils; discard tube after use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical cream, ointment: For external use only; area may be covered with gauze if desired",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F198501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal: Eradication of nasal colonization with MRSA in adult patients and healthcare workers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Treatment of impetigo or secondary infected traumatic skin lesions due to",
"     <i>",
"      S. aureus",
"     </i>",
"     and",
"     <i>",
"      S. pyogenes",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F198554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intranasal: Surgical prophylaxis to prevent wound infections",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F198564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Bactroban&reg; may be confused with bacitracin, baclofen, Bactrim&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F198555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Cellulitis, dermatitis, dry skin, erythema, hives, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, nausea, taste perversion, ulcerative stomatitis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, edema, pain, stinging, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blepharitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Ear pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, pharyngitis, rhinitis, upper respiratory tract congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Secondary wound infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F198504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to mupirocin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F198491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: If skin irritation occurs, discontinue use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polyethylene glycol: Potentially toxic amounts of polyethylene glycol contained in some topical products may be absorbed percutaneously in patients with extensive burns or open wounds.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only; avoid contact with eyes. Not for treatment of pressure sores.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F198495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F198497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F198508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women; use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F198524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F198507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Bactroban External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (15 g): $77.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Mupirocin Calcium External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (15 g): $69.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Centany AT External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (1): $179.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Bactroban External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (22 g): $93.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Bactroban Nasal Nasal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (1 g): $12.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Centany External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (30 g): $179.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Mupirocin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (22 g): $42.75",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F198509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bacidal (TH);",
"     </li>",
"     <li>",
"      Bactermin (TW);",
"     </li>",
"     <li>",
"      Bactex (TH);",
"     </li>",
"     <li>",
"      Bactifree (PH);",
"     </li>",
"     <li>",
"      Bactocin (PH);",
"     </li>",
"     <li>",
"      Bactoderm (ID, IL);",
"     </li>",
"     <li>",
"      Bactokil (TH);",
"     </li>",
"     <li>",
"      Bactroban (AE, AR, AT, AU, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CR, CY, CZ, DK, DO, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, MX, NE, NG, NI, NL, NZ, OM, PA, PH, PK, PL, PR, PT, PY, QA, RU, SA, SC, SD, SE, SG, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Bagobiotic (EC);",
"     </li>",
"     <li>",
"      Banbact (TH);",
"     </li>",
"     <li>",
"      Betrion (HR);",
"     </li>",
"     <li>",
"      Dermasafe (TW);",
"     </li>",
"     <li>",
"      Dermatech Bantix (CO);",
"     </li>",
"     <li>",
"      Esroban (KP);",
"     </li>",
"     <li>",
"      Foskina (PH);",
"     </li>",
"     <li>",
"      Mertus (ID);",
"     </li>",
"     <li>",
"      Mupicin (PH);",
"     </li>",
"     <li>",
"      Mupider (SG);",
"     </li>",
"     <li>",
"      Mupiderm (FR);",
"     </li>",
"     <li>",
"      Mupiral (EC);",
"     </li>",
"     <li>",
"      Mupiroban (KP);",
"     </li>",
"     <li>",
"      Mupirox (PE);",
"     </li>",
"     <li>",
"      Muporin (TH);",
"     </li>",
"     <li>",
"      Muprin (HK, MY, PH);",
"     </li>",
"     <li>",
"      Pibaksin (ID);",
"     </li>",
"     <li>",
"      Sinpebac (MX);",
"     </li>",
"     <li>",
"      Spectroderm (PE);",
"     </li>",
"     <li>",
"      Supirocin (MY, SG);",
"     </li>",
"     <li>",
"      Turixin (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F198490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to bacterial isoleucyl transfer-RNA synthetase resulting in the inhibition of protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F198503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Penetrates outer layers of skin; systemic absorption minimal through intact skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Skin: 3% to monic acid (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Blumer JL, Lemon E, O'Horo J, et al, &ldquo;Changing Therapy for Skin and Soft Tissue Infections in Children: Have We Come Full Circle?&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1987, 6(1):117-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/30/33252/abstract-text/3547287/pubmed\" id=\"3547287\" target=\"_blank\">",
"        3547287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Britton JW, Fajardo JE, and Krafte-Jacobs B, &ldquo;Comparison of Mupirocin and Erythromycin in the Treatment of Impetigo,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 117(5):827-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/30/33252/abstract-text/2121951/pubmed\" id=\"2121951\" target=\"_blank\">",
"        2121951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldfarb J, Crenshaw D, O'Horo J, et al, &ldquo;Randomized Clinical Trial of Topical Mupirocin Versus Oral Erythromycin for Impetigo,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1988, 32(12):1780-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/30/33252/abstract-text/3149884/pubmed\" id=\"3149884\" target=\"_blank\">",
"        3149884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perl TM, Cullen JJ, Wenzel RP, et al, &ldquo;Intranasal Mupirocin to Prevent Postoperative",
"      <i>",
"       Staphylococcus aureus",
"      </i>",
"      Infections,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2002, 346(24):1871-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?32/30/33252/abstract-text/12063371/pubmed\" id=\"12063371\" target=\"_blank\">",
"        12063371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9668 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33252=[""].join("\n");
var outline_f32_30_33252=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198518\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198519\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198557\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198521\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198538\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198522\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198500\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198487\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803172\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198501\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198554\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198564\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198555\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198504\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198491\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299730\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198495\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198497\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198508\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198524\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198507\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198509\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198490\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F198503\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9668\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9668|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/63/6132?source=related_link\">",
"      Mupirocin: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=related_link\">",
"      Mupirocin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_30_33253="Myeloma cast II- light microscopy";
var content_f32_30_33253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F70405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F70405&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myeloma cast II- light microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph showing classic features of cast nephropathy including: 1) obstructed tubule with a fractured dense cast; 2) giant cell reaction in the lower left part of the tubule; and 3) interstitial infiltrate with macrophages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33253=[""].join("\n");
var outline_f32_30_33253=null;
var title_f32_30_33254="Pylephlebitis";
var content_f32_30_33254=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pylephlebitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33254/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33254/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33254/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33254/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33254/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33254/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/30/33254/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pylephlebitis, or infective suppurative thrombosis of the portal vein, is a serious condition with significant morbidity and mortality, which can complicate intraabdominal sepsis of any etiology. Although universally fatal in the preantibiotic era [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1\">",
"     1",
"    </a>",
"    ], the outcome of this infection has improved somewhat with modern diagnostic and therapeutic modalities. Curiously, however, reports of the diagnosis have increased in the last 15 years, possibly as a result of newer, more sensitive imaging techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The portal vein is formed by the union of the superior mesenteric vein with the splenic veins. The portal system drains blood from the abdominal section of the gastrointestinal tract, with the exception of the lower part of the rectum.",
"   </p>",
"   <p>",
"    Pylephlebitis begins with thrombophlebitis of small veins draining an area of infection. Extension of the thrombophlebitis into larger veins leads to septic thrombophlebitis of the portal vein, which can extend further to involve the mesenteric veins [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/3\">",
"     3",
"    </a>",
"    ]. In a review of case reports, the superior mesenteric vein was involved in 42 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/4\">",
"     4",
"    </a>",
"    ]. Thrombus involved the splenic vein and intrahepatic branches of the portal vein in 12 and 39 percent of cases, respectively. Mesenteric vein involvement can lead to bowel ischemia, infarction and death.",
"   </p>",
"   <p>",
"    An associated hypercoagulable state is found in some cases of pylephlebitis. As an example, in one series of 44 cases, 18 were hypercoagulable due to clotting factor deficiencies, malignant conditions, or AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pylephlebitis can complicate any intraabdominal or pelvic infection that occurs in the region drained by the portal venous system, especially diverticulitis and appendicitis (",
"    <a class=\"graphic graphic_figure graphicRef71532 \" href=\"UTD.htm?18/14/18663\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. Contiguous infection (eg, cholangitis or infected choledocholithiasis) can also lead to this complication [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. In addition, pylephlebitis has been associated with inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/6,9,10\">",
"     6,9,10",
"    </a>",
"    ], pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/4\">",
"     4",
"    </a>",
"    ], hemorrhoidal banding [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/11\">",
"     11",
"    </a>",
"    ], and has occurred as a complication of the intragastric migration of a silicone gastric band [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/12\">",
"     12",
"    </a>",
"    ] and following a CT-guided liver biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/13\">",
"     13",
"    </a>",
"    ]. A precipitating focus was identified in 13 of 18 cases (68 percent) in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a 1948 report, the most common inciting infection was appendicitis, accounting for all 21 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the incidence of pylephlebitis following appendicitis significantly decreased with the introduction of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1\">",
"     1",
"    </a>",
"    ]. One of the most frequent foci currently is diverticulitis, which accounted for 6 of 18 cases in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ]. Although diverticulitis is a common cause of pylephlebitis, pylephlebitis remains a rare complication of diverticulitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The age range of affected patients is wide (6 to 75 years), which may partially be influenced by the number of patients with appendicitis as an inciting etiology. The mean age of patients with pylephlebitis is approximately 42 years, and in one review, 24 percent were aged &lt;18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia, which is frequently polymicrobial, occurred in 88 percent of cases in one series; the most common bloodstream isolates were Bacteroides fragilis and Escherichia coli, but other organisms (eg, Aeromonas hydrophila, streptococci, Proteus mirabilis, Klebsiella pneumoniae, anaerobic streptococci, and Clostridium spp) were also isolated [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ]. Yeasts, streptococci, staphylococci, and Citrobacter have also been described, but enterococci are an uncommon cause of this entity [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain, which is not necessarily severe, and fever are the most common presenting symptoms of pylephlebitis. In one report, all 44 patients had these two complaints [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/5\">",
"     5",
"    </a>",
"    ]. By contrast, 100 percent had fever but only 14 (74 percent) complained of abdominal pain in another review of 19 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ]. Other symptoms have included rigors, nausea, vomiting, and headache [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1,2,15\">",
"     1,2,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical signs may include right upper quadrant or generalized abdominal tenderness, hepatomegaly, and jaundice. However, jaundice appears to be unusual in pylephlebitis unless there is associated cholangitis or liver abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ]. Splenomegaly has been reported in 10 to 25 percent of cases of pylephlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/4,16\">",
"     4,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients may have minimal or no clinical features referable to the primary focus of infection, similar to patients with liver abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link\">",
"     \"Pyogenic liver abscess\"",
"    </a>",
"    .) Although pylephlebitis usually presents as an acute illness, it may also present with a chronic or stuttering course over weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/3,17\">",
"     3,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocytosis is a common finding [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1,9,15,18\">",
"     1,9,15,18",
"    </a>",
"    ], but both a normal leukocyte count [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2,16,18\">",
"     2,16,18",
"    </a>",
"    ] and neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/6\">",
"     6",
"    </a>",
"    ] have also been described. Abnormal liver function tests, especially three- to fourfold increases in alkaline phosphatase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1,6,9,15\">",
"     1,6,9,15",
"    </a>",
"    ] and 5- to 10-fold increases in gamma glutamyl transferase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/7,9\">",
"     7,9",
"    </a>",
"    ], are noted in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1\">",
"     1",
"    </a>",
"    ]. However, in keeping with the relative infrequency of clinical jaundice, two- to sixfold increases in serum bilirubin occur only in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1,6,9,15\">",
"     1,6,9,15",
"    </a>",
"    ]. The inciting intraabdominal sepsis or complicating hepatic abscesses may also contribute to hepatic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver abscess and bowel ischemia may complicate pylephlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1,19-21\">",
"     1,19-21",
"    </a>",
"    ]. Portal hypertension may be a long term complication of pylephlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/6\">",
"     6",
"    </a>",
"    ]; sequelae of portal hypertension can include a dilated splenic vein and numerous venous collaterals in the hepatoduodenal ligament [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link\">",
"     \"Pyogenic liver abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pylephlebitis requires the demonstration of portal vein thrombosis (pylethrombosis) usually accompanied by bacteremia in a febrile patient [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/18\">",
"     18",
"    </a>",
"    ]. The diagnosis is frequently delayed because pylephlebitis is not considered since it is an uncommon condition, or because symptoms are nonspecific, clinical signs are typically lacking from the primary focus of infection, and there may be poor visualization of the portal vein. The diagnosis was most often made at laparotomy or postmortem in the past, but modern imaging techniques now facilitate an earlier diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia has been documented in 23 to 88 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. For this reason, blood cultures should be obtained in any febrile patient with abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The demonstration of thrombus in the portal vein is an important component of the diagnosis of pylephlebitis but is not sufficient by itself. The diagnostic imaging modality of choice depends on the expertise at the institution where the studies are performed. Both computed tomography (CT) scanning and ultrasonography can demonstrate thrombus in the portal vein, with or without associated mesenteric vein thrombus [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/16\">",
"     16",
"    </a>",
"    ]. In up to 18 percent of cases, gas can be visualized in the portal system [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/4\">",
"     4",
"    </a>",
"    ]. We prefer the CT scan as the imaging study because of the additional ability to identify an underlying focus of infection elsewhere in the abdomen or pelvis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Computerized tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CT scan is diagnostic when it demonstrates portal vein thrombosis in a patient with a clinical picture consistent with pylephlebitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1,16,22\">",
"     1,16,22",
"    </a>",
"    ]. CT scanning has also been useful in defining a precipitating focus of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography can demonstrate echogenic material within the lumen of the portal vein and can also be used to evaluate progression or extension of clot and subsequent recanalization [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/6\">",
"     6",
"    </a>",
"    ]. Color flow Doppler ultrasonography may improve diagnostic accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/1\">",
"     1",
"    </a>",
"    ]. Intraoperative ultrasonography has also been used to confirm the diagnosis of pylephlebitis when this entity is suspected preoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics constitute the major treatment approach to pylephlebitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of empiric antibiotics in pylephlebitis depends on the probable source of infection and the likely organisms. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Microbiology'",
"    </a>",
"    above.) Infection is often polymicrobial with both gram-negative aerobes and anaerobes, especially B. fragilis. Successful antibiotic regimens have included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/23\">",
"     23",
"    </a>",
"    ], third generation cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/6\">",
"     6",
"    </a>",
"    ], fluoroquinolones [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/6\">",
"     6",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/6\">",
"     6",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/24/43396?source=see_link\">",
"     lincomycin",
"    </a>",
"    (not available in the United States) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Recommended regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pylephlebitis is an uncommon infection, and thus, no randomized controlled studies have evaluated empiric antibiotic regimens for this disease. Treatment regimens are based on coverage of the most likely organisms to cause infection in this setting and small case series. We recommend that empiric treatment include broad-spectrum antibiotics until culture results are available. Patients should be treated at least initially with parenteral antibiotics.",
"   </p>",
"   <p>",
"    Appropriate antibiotics include any of the following parenteral regimens:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg every eight hours) PLUS one of the following,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g daily) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (2 g every six hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (400 mg every 12 hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (500 mg daily)",
"     </li>",
"     <li>",
"      Monotherapy with a",
"      <span class=\"nowrap\">",
"       beta-lactam/beta-lactamase",
"      </span>",
"      inhibitor, such as,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"        piperacillin",
"       </a>",
"       /tazobactam",
"      </span>",
"      (4.5 g every six hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      (3.1 g every four hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      (3 g every six hours)",
"     </li>",
"     <li>",
"      Monotherapy with a carbapenem, such as, imipenem (500 mg every six hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (1 g every eight hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      (1 g daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial antibiotic choice should be modified if blood or surgical (from the underlying focus of infection) culture results and antimicrobial susceptibility testing are available. Susceptibility testing for anaerobes are not routinely performed but should be considered, especially in patients who are failing therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical duration of antibiotic therapy is at least four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ]. Parenteral antibiotics are given until there is significant clinical response, usually about two to three weeks. The remainder of the antibiotic course can be completed with oral agents, such as, the combination of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and a fluoroquinolone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective randomized controlled studies and no consensus on the use of anticoagulation in pylephlebitis. The rationale for anticoagulation in acute pylephlebitis is the prevention of thrombus extension and its sequelae.",
"   </p>",
"   <p>",
"    In a report of 100 selected cases of pylephlebitis from the literature, 35 received anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/4\">",
"     4",
"    </a>",
"    ]. There were fewer deaths among those who received anticoagulation compared with those who received antibiotics alone (6 versus 22 percent). Similarly, a retrospective review of 44 patients with pylephlebitis, diagnosed with CT scan and consistent clinical symptoms, found that patients who received anticoagulation had a better outcome than those who did not (0 of 12 versus 5 of 32 deaths) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/5\">",
"     5",
"    </a>",
"    ]. Based upon these findings, the authors of this review suggest the following role of anticoagulation therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticoagulation is probably unnecessary in the patient with normal clotting function and thrombosis isolated to the portal vein. However, if there is mesenteric vein involvement, patients may benefit from anticoagulation, since the risk of bowel ischemia and infarction may be higher.",
"     </li>",
"     <li>",
"      Anticoagulation should be considered in the patient with a hypercoagulable state (eg, due to a neoplasm or clotting factor deficiency).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further support for anticoagulation in patients with pylephlebitis comes from a retrospective case series of patients with recent portal or mesenteric thrombosis, which found that recanalization occurred in 25 of 27 patients given anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, a case report of anticoagulation after extension of thrombus documented prompt resolution of the clot [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/6\">",
"     6",
"    </a>",
"    ]. The authors of this case report suggest that if there is acute extension of thrombosis, documented progression, or persistent fever unresponsive to antibiotic therapy, anticoagulation should be considered.",
"   </p>",
"   <p>",
"    Bacteroides spp appear to promote coagulation, as these organisms produce enzymes that break down",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and Bacteroides spp surface components promote fibrin clotting [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/3\">",
"     3",
"    </a>",
"    ]. The isolation of this organism from a patient may influence the decision, favoring anticoagulation.",
"   </p>",
"   <p>",
"    However, other studies have noted no benefit from anticoagulation. A retrospective review of 19 patients with pylephlebitis found no clear improvement attributed to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When anticoagulation is used, the clinical endpoint is uncertain. Recanalization has been documented in some cases, but the length of time required for this to occur is unknown.",
"   </p>",
"   <p>",
"    Thrombolytic therapy is an additional option when thrombosis progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/6\">",
"     6",
"    </a>",
"    ], but there is minimal experience with this treatment in pylephlebitis and no conclusive evidence of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest not treating most patients with anticoagulation unless there is evidence of progression of thrombosis or continued fever or bacteremia despite antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Percutaneous techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter insertion into the portal vein with aspiration of thrombus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pus has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Intraportal infusion of antibiotics has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/26\">",
"     26",
"    </a>",
"    ]. Further clinical experience is required before this technique can be routinely recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is not usually required for the management of pylephlebitis. However, surgical drainage of the precipitating focus may be necessary in some cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pylephlebitis was uniformly fatal in the 20 cases reported in 1948, secondary to appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/14\">",
"     14",
"    </a>",
"    ]. Even with newer available antibiotics, the condition continues to have an appreciable mortality rate, ranging from 11 to 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33254/abstract/2,5\">",
"     2,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pylephlebitis or infective suppurative thrombosis of the portal vein is a serious condition with significant morbidity and mortality, which can complicate intraabdominal sepsis of any etiology. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pylephlebitis begins with thrombophlebitis of small veins draining an area of infection. Extension of the thrombophlebitis into larger veins leads to septic thrombophlebitis of the portal vein, which can extend further to involve the mesenteric veins. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common predisposing infections leading to pylephlebitis are diverticulitis and appendicitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bacteremia, which is frequently polymicrobial, occurred in 88 percent of cases in one series; the most common bloodstream isolates were Bacteroides fragilis and Escherichia coli. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Abdominal pain, which is not necessarily severe, and fever are the most common presenting symptoms of pylephlebitis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of pylephlebitis requires the demonstration of portal vein thrombosis (pylethrombosis) usually accompanied by bacteremia in a febrile patient. We prefer the CT scan as the imaging study because of the additional ability to identify an underlying focus of infection elsewhere in the abdomen or pelvis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend empiric treatment of pylephlebitis include parenteral broad-spectrum antibiotics until culture results are available (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Typical treatment regimens include one of the following (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Antibiotics'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (500 mg every eight hours) PLUS one of the following,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 g daily) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35735?source=see_link\">",
"       cefotaxime",
"      </a>",
"      (2 g every six hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      (400 mg every 12 hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      (500 mg daily)",
"     </li>",
"     <li>",
"      Monotherapy with a",
"      <span class=\"nowrap\">",
"       beta-lactam/beta-lactamase",
"      </span>",
"      inhibitor, such as,",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35030?source=see_link\">",
"        piperacillin",
"       </a>",
"       /tazobactam",
"      </span>",
"      (4.5 g every six hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/45/42710?source=see_link\">",
"       ticarcillin-clavulanate",
"      </a>",
"      (3.1 g every four hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1160?source=see_link\">",
"       ampicillin-sulbactam",
"      </a>",
"      (3 g every six hours)",
"     </li>",
"     <li>",
"      Monotherapy with a carbapenem, such as, imipenem (500 mg every six hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"       meropenem",
"      </a>",
"      (1 g every eight hours) OR",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"       ertapenem",
"      </a>",
"      (1 g daily)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial antibiotic choice should be modified once culture results and antimicrobial susceptibility testing are available. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Recommended regimens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical duration of antibiotic therapy is at least four to six weeks. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       NOT",
"      </strong>",
"      treating most patients with anticoagulation unless there is evidence of progression of thrombosis or continued fever or bacteremia despite antibiotic therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/1\">",
"      Saxena R, Adolph M, Ziegler JR, et al. Pylephlebitis: a case report and review of outcome in the antibiotic era. Am J Gastroenterol 1996; 91:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/2\">",
"      Plemmons RM, Dooley DP, Longfield RN. Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect Dis 1995; 21:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/3\">",
"      Kasper DL, Sahani D, Misdraji J. Case records of the Massachusetts General Hospital. Case 25-2005. A 40-year-old man with prolonged fever and weight loss. N Engl J Med 2005; 353:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/4\">",
"      Kanellopoulou T, Alexopoulou A, Theodossiades G, et al. Pylephlebitis: an overview of non-cirrhotic cases and factors related to outcome. Scand J Infect Dis 2010; 42:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/5\">",
"      Baril N, Wren S, Radin R, et al. The role of anticoagulation in pylephlebitis. Am J Surg 1996; 172:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/6\">",
"      Duffy FJ Jr, Millan MT, Schoetz DJ Jr, Larsen CR. Suppurative pylephlebitis and pylethrombosis: the role of anticoagulation. Am Surg 1995; 61:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/7\">",
"      Joly V, Belmatoug N, Sibert A, et al. Septic thrombophlebitis of the portal vein. Clin Infect Dis 1996; 23:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/8\">",
"      Tsao YT, Lin SH, Cheng CJ, Chang FY. Pylephlebitis associated with acute infected choledocholithiasis. Am J Med Sci 2006; 332:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/9\">",
"      Tung JY, Johnson JL, Liacouras CA. Portal-mesenteric pylephlebitis with hepatic abscesses in a patient with Crohn's disease treated successfully with anticoagulation and antibiotics. J Pediatr Gastroenterol Nutr 1996; 23:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/10\">",
"      Baddley JW, Singh D, Correa P, Persich NJ. Crohn's disease presenting as septic thrombophlebitis of the portal vein (pylephlebitis): case report and review of the literature. Am J Gastroenterol 1999; 94:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/11\">",
"      Chau NG, Bhatia S, Raman M. Pylephlebitis and pyogenic liver abscesses: a complication of hemorrhoidal banding. Can J Gastroenterol 2007; 21:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/12\">",
"      De Roover A, Detry O, Coimbra C, et al. Pylephlebitis of the portal vein complicating intragastric migration of an adjustable gastric band. Obes Surg 2006; 16:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/13\">",
"      Tandon R, Davidoff A, Worthington MG, Ross JJ. Pylephlebitis after CT-guided percutaneous liver biopsy. AJR Am J Roentgenol 2005; 184:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/14\">",
"      SORO Y. Pylephlebitis and liver abscesses due to appendicitis. J Int Coll Surg 1948; 11:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/15\">",
"      Sakamoto H, Suga M, Ozeki I, et al. Subcapsular hematoma of the liver and pylethrombosis in the setting of cholestatic liver injury. J Gastroenterol 1996; 31:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/16\">",
"      Farin P, Paajanen H, Miettinen P. Intraoperative US diagnosis of pylephlebitis (portal vein thrombosis) as a complication of appendicitis: a case report. Abdom Imaging 1997; 22:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/17\">",
"      Wireko M, Berry PA, Brennan J, Aga R. Unrecognized pylephlebitis causing life-threatening septic shock: a case report. World J Gastroenterol 2005; 11:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/18\">",
"      Dean JW, Trerotola SO, Harris VJ, et al. Percutaneous management of suppurative pylephlebitis. J Vasc Interv Radiol 1995; 6:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/19\">",
"      Nishimori H, Ezoe E, Ura H, et al. Septic thrombophlebitis of the portal and superior mesenteric veins as a complication of appendicitis: report of a case. Surg Today 2004; 34:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/20\">",
"      Brown KT, Gandhi RT, Covey AM, et al. Pylephlebitis and liver abscess mimicking hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2003; 2:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/21\">",
"      Chang TN, Tang L, Keller K, et al. Pylephlebitis, portal-mesenteric thrombosis, and multiple liver abscesses owing to perforated appendicitis. J Pediatr Surg 2001; 36:E19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/22\">",
"      Balthazar EJ, Gollapudi P. Septic thrombophlebitis of the mesenteric and portal veins: CT imaging. J Comput Assist Tomogr 2000; 24:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/23\">",
"      Perez-Cruet MJ, Grable E, Drapkin MS, et al. Pylephlebitis associated with diverticulitis. South Med J 1993; 86:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/24\">",
"      Condat B, Pessione F, Helene Denninger M, et al. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/25\">",
"      Sherigar R, Amir KA, Bobba RK, et al. Abdominal pain secondary to pylephlebitis: an uncommon disease of the portal venous system, treated with local thrombolytic therapy. Dig Dis Sci 2005; 50:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/26\">",
"      Vivas I, Bilbao JI, Mart&iacute;nez-Cuesta A, et al. Combination of various percutaneous techniques in the treatment of pylephlebitis. J Vasc Interv Radiol 2000; 11:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33254/abstract/27\">",
"      Pelsang RE, Johlin F, Dhadha R, et al. Management of suppurative pylephlebitis by percutaneous drainage: placing a drainage catheter into the portal vein. Am J Gastroenterol 2001; 96:3192.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2713 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-2A8E9B1E90-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33254=[""].join("\n");
var outline_f32_30_33254=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Computerized tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Recommended regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Percutaneous techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2713\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2713|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/14/18663\" title=\"figure 1\">",
"      Pylephlebitis liver abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=related_link\">",
"      Pyogenic liver abscess",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_30_33255="Surgical treatment of pulp space infection";
var content_f32_30_33255=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F59879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F59879&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Surgical treatment of pulp space infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 595px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Most patients with a pulp abscess require surgical intervention because the infection may be more extensive than the symptoms and clinical appearance suggest.",
"    <br>",
"     Panel A depicts the incisions used to drain a pulp abscess. Left: Lateral incision. Right: Palmar incision.",
"     <br>",
"      Panel B illustrates the surgical approach to the pulp abscess cavity. The lateral incision enters the abscess cavity dorsal to the neurovascular bundle and palmar to the palmar cortex of the distal phalanx. The palmar incision enters the abscess cavity directly from the palmar aspect.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33255=[""].join("\n");
var outline_f32_30_33255=null;
var title_f32_30_33256="Septic bursitis";
var content_f32_30_33256=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Septic bursitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33256/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33256/contributors\">",
"     Camille N Kotton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33256/contributors\">",
"     Jonathan Kay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33256/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33256/contributors\">",
"     Zacharia Isaac, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33256/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33256/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/30/33256/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bursitis is an inflammation or degeneration of the sac-like structures that form in utero to protect the soft tissues from underlying bony prominences [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/1\">",
"     1",
"    </a>",
"    ]. Septic bursitis refers to inflammation of the bursa that is due to infection, typically resulting from bacterial inoculation that is either direct (eg, puncture wound), spread from nearby soft tissues (eg, cellulitis), or hematogenous (eg, bacterial endocarditis). Much less commonly, mycobacteria, fungi, or algae are the causative agents.",
"   </p>",
"   <p>",
"    Nonseptic bursitis due to trauma, repetitive injury, crystal diseases, and other systemic disorders is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are more than 150 bursae in the human body. Bursae may be divided by location into those that are superficial or deep. Superficial bursae are subcutaneous and separate skin from deeper tissues such as periosteum or ligaments. Deep bursae serve to reduce friction between fibrous structures such as tendons from adjacent bone. Bursae are lined by synovial cells, which under ordinary circumstances produce a small amount of lubricating fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Superficial bursae",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superficial or subcutaneous bursae are predisposed to infection as a result of skin trauma. Direct inoculation due to puncture of the overlying skin, or contiguous spread from cellulitis are presumed to be the most common mechanisms involved in septic superficial bursitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The majority of reported cases have been in men [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Trauma to the skin and bursa may be occupational, due to recreational activities, or related to concomitant diseases. Among these the following are notable [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2,8-10\">",
"     2,8-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Olecranon septic bursitis &mdash; Due to repetitive trauma in plumbers, carpenters, miners, athletes, patients with chronic obstructive pulmonary disease (possibly the result of leaning on the elbows) and those receiving chronic hemodialysis via vascular access in the arm.",
"     </li>",
"     <li>",
"      Prepatellar or infrapatellar septic bursitis &mdash; In athletes and those with kneeling occupations such as housemaids, carpet layers, clergy, and gardeners",
"     </li>",
"     <li>",
"      Ischiogluteal septic bursitis &mdash; In spinal cord injured patients and weavers",
"     </li>",
"     <li>",
"      Bunions &mdash; A bursa may form over the medial aspect of the 1st metatarsophalangeal joint in patients with hallux valgus where pressure due to poorly fitting shoes can cause skin breakdown and bursal infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Deep bursae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct inoculation of deep bursa is uncommon, but iatrogenic infection resulting from bursal injections of glucocorticoids (eg, subacromial, iliopsoas, or trochanteric bursae) may rarely occur [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/11\">",
"     11",
"    </a>",
"    ]. A history of recent joint aspiration and injection, or acupuncture treatment should alert the clinician to a possible deep septic bursitis. In the absence of a known inoculation, infection of deep bursae are presumed to be due to hematogenous seeding or spread from an adjacent septic site such as contiguous septic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"     \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to local factors that predispose to septic bursitis, other host factors that lead to an increased amount of bursal fluid or tissue (eg, rheumatoid arthritis, tophaceous gout), loss of skin integrity, or impaired response to infection (eg, diabetes mellitus, alcohol abuse) may increase the risk of septic bursitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/3,12,13\">",
"     3,12,13",
"    </a>",
"    ]. A community based study of septic olecranon bursitis found that one third of patients had at least one comorbid illness [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/6\">",
"     6",
"    </a>",
"    ]. It is unclear whether immunosuppressed states such as",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    increase the risk of septic bursitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]. An immunosuppressed patient may require a longer duration of antibiotic treatment than an otherwise healthy host [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/5,15\">",
"     5,15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with septic bursitis typically present with pain and peribursal erythema and warmth, often in the setting of diabetes, alcoholism, or immunosuppression. Fever is present in the majority of patients with septic bursitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. Peribursal edema and pain on movement favor a diagnosis of bursal sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2\">",
"     2",
"    </a>",
"    ]. When compared to patients with non-infectious bursitis, those with acute septic bursitis may be more likely to present earlier and have fever and more pain, erythema, warmth, and tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/7\">",
"     7",
"    </a>",
"    ]. The distinction from non-infectious bursitis may be more difficult in subacute or chronic infection.",
"   </p>",
"   <p>",
"    As noted earlier, common sites for septic bursitis are the superficially located olecranon, prepatellar, and infrapatellar bursae. For these superficially located bursae, adjacent joint motion may be relatively preserved when compared to the marked limitation of joint motion that typically accompanies septic arthritis.",
"   </p>",
"   <p>",
"    Leukocytosis, neutrophilia, and an increased proportion of immature neutrophils (ie, bandemia), may be noted [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/5\">",
"     5",
"    </a>",
"    ]. ESR and CRP are usually elevated. Bacteremia is more often a feature of deep than superficial septic bursitis and is relatively rare [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/10\">",
"     10",
"    </a>",
"    ]. In one series of 343 patients hospitalized with bursitis, in the 71 cases for which blood cultures were obtained prior to initiation of antibiotics, blood cultures yielded the same organism as bursal specimens only three cases (4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/16\">",
"     16",
"    </a>",
"    ]. In another series, blood cultures were positive in 12 of 62 patients (19.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus aureus is the causative organism in 80 percent or more of cases of culture proven septic bursitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2,6,7,10,16\">",
"     2,6,7,10,16",
"    </a>",
"    ]. Streptococci of various species are the next most commonly reported cause, and are frequently of beta-hemolytic strains [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2,3,16\">",
"     2,3,16",
"    </a>",
"    ]. Less commonly reported organisms causing acute septic bursitis include: coagulase-negative staphylococci, Enterococcus, Escherichia coli, Pseudomonas aeruginosa, and anaerobes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2,4,17\">",
"     2,4,17",
"    </a>",
"    ]. Polymicrobial infections constitute a significant proportion of non-S. aureus bursitis, ranging from 10 to 36 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2,4,16\">",
"     2,4,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subacute or chronic bursitis may be due to Brucella abortus, Mycobacteria (both M. tuberculosis and atypical mycobacteria, such as M. kansasii [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/18\">",
"     18",
"    </a>",
"    ]), fungi such as Candida, dematiaceous fungi [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/19\">",
"     19",
"    </a>",
"    ], molds, and algae including Prototheca [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/10,20-31\">",
"     10,20-31",
"    </a>",
"    ]. Systemic infection should be considered in cases of bursitis caused by Brucella or M. tuberculosis in endemic regions [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence or absence of a history of trauma is not helpful diagnostically [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2\">",
"     2",
"    </a>",
"    ]. When superficial bursae are involved there is usually marked erythema and warmth. Other suggestive findings are the presence of a puncture wound or abrasion of the skin overlying the involved bursa.",
"   </p>",
"   <p>",
"    Aspiration of fluid from any acutely inflamed bursa is warranted in order to assess for infection. Plain film radiography using soft tissue technique or ultrasonography of the bursa and adjacent soft tissues may be indicated if there is concern about a foreign body. In the absence of a history of significant trauma or penetrating wound, imaging of the olecranon or knee bursae and adjacent joints is generally unnecessary for diagnostic purposes. Ultrasonography, computed tomography (CT) scanning, or magnetic resonance imaging (MRI) may be necessary to assess for the presence of a bursal effusion in cases of suspected infection of deep bursae [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bursa aspiration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspiration of bursal fluid is indicated whenever there is an effusion and septic bursitis is suspected because of the presence of one or more of the following clinical features: pain, local inflammation, or fever. Bursal fluid may be obtained by bedside needle aspiration in most cases of superficial prepatellar (",
"    <a class=\"graphic graphic_picture graphicRef61701 \" href=\"UTD.htm?8/18/8480\">",
"     picture 1",
"    </a>",
"    ) and olecranon (",
"    <a class=\"graphic graphic_picture graphicRef72647 \" href=\"UTD.htm?21/62/22496\">",
"     picture 2",
"    </a>",
"    ) bursitis. The techniques for prepatellar and olecranon bursal aspiration are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28422?source=see_link&amp;anchor=H2#H2\">",
"     \"Knee bursitis\", section on 'Prepatellar bursitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14983?source=see_link&amp;anchor=H29#H29\">",
"     \"Evaluation of elbow pain in adults\", section on 'Olecranon bursa aspiration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aspiration and drainage of deep bursae (eg, iliopsoas) typically require image assisted needle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    catheter placement using ultrasonography or CT guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bursal fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory analysis of bursal fluid consists of determination of the nucleated cell count (white cell count), Gram stain, and culture for bacteria. Inoculation into liquid media (ie, blood culture bottles) is significantly more sensitive than direct culture on solid media [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/7\">",
"     7",
"    </a>",
"    ]. Fungal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mycobacterial stains and cultures may be appropriate in selected patients (eg, gardeners, fishermen, and immunosuppressed patients, at risk for sporotrichosis, Mycobacterium marinum, and atypical infections, respectively). Anaerobic infection, although rare, should be considered when cultures are initially negative but infectious signs and symptoms persist [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cell count &mdash; Lower bursal fluid nucleated cell counts are found with bacterial infection of the bursa when compared to septic arthritis, in which synovial fluid nucleated cell counts are typically greater than",
"      <span class=\"nowrap\">",
"       50,000/mm3",
"      </span>",
"      (5.0 x",
"      <span class=\"nowrap\">",
"       10(9)/L).",
"      </span>",
"      This was illustrated in a study, in which 8 of 13 patients with culture-proven septic bursitis had bursal fluid leukocyte counts less than",
"      <span class=\"nowrap\">",
"       20,000/mm3",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/13\">",
"       13",
"      </a>",
"      ]. In contrast, only 1 of 18 patients with septic arthritis had synovial fluid nucleated cell counts less than that threshold. The lowest bursal fluid WBC count in a culture-proven case of septic bursitis was",
"      <span class=\"nowrap\">",
"       1200/mm3",
"      </span>",
"      (1.2 x",
"      <span class=\"nowrap\">",
"       10(9)/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"       \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"      </a>",
"      .) Immunocompromised hosts may have a more limited inflammatory response.",
"      <br/>",
"      <br/>",
"      The threshold value of the nucleated cell count affects the sensitivity and specificity when used as a diagnostic test for septic bursitis. A threshold for bursal leukocytosis of",
"      <span class=\"nowrap\">",
"       &gt;2000/mm3",
"      </span>",
"      [&gt;2.0 x",
"      <span class=\"nowrap\">",
"       10(9)/L]",
"      </span>",
"      was noted to have a sensitivity and specificity for septic bursitis of 94 and 79 percent, respectively, in a study of 36 patients with olecranon or prepatellar bursitis [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gram stain &mdash; The reported sensitivity of Gram stain in detecting organisms ranges from 15 to 100 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/10,12,13\">",
"       10,12,13",
"      </a>",
"      ]. When an organism is seen, it may be helpful in guiding antibiotic therapy.",
"     </li>",
"     <li>",
"      Crystal identification &mdash; Compensated polarized microscopy by an experienced clinician or technician is recommended to assess for the presence of crystals and, if present, to classify them on the basis of their shape and birefringence. The technique is the same as that employed to identify crystals in joint fluid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=see_link\">",
"       \"Synovial fluid analysis and the diagnosis of septic arthritis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bursa fluid glucose &mdash; The diagnostic utility of bursal fluid glucose is uncertain. In one report including 30 patients with olecranon or prepatellar bursitis (10 of whom had septic bursitis), the mean bursal fluid glucose concentration was significantly lower in septic than in nonseptic bursal fluids [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/35\">",
"       35",
"      </a>",
"      ]. A bursa fluid glucose:serum glucose ratio of &lt;50 percent was observed almost exclusively in cases of septic bursitis. However, the bursa fluid glucose concentration also is low in nonseptic bursitis observed in patients with rheumatoid arthritis [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/36\">",
"       36",
"      </a>",
"      ]. Thus, the diagnosis of septic bursitis cannot be made on the basis of bursal fluid glucose concentration without culture of the bursal fluid.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are expensive and are typically not helpful in the setting of an acute superficial (eg, olecranon or prepatellar) bursitis. When bursitis is of traumatic origin, however, foreign body penetration may be revealed by plain radiographs of soft tissue or with MRI. As noted above, if septic bursitis of a deep bursa is suspected, imaging with ultrasonography, CT, or MRI may be required to confirm the presence of bursal fluid, associated abscesses, or affected adjacent structures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/10\">",
"     10",
"    </a>",
"    ]. Ultrasonography or CT can be used to guide needle aspiration of the bursa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Additional Studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In cases of suspected brucellosis, serum serology may be helpful for diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations, diagnosis, and treatment of brucellosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If bursal resection is necessary (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Indication for surgical intervention'",
"    </a>",
"    below), histologic examination of excised tissue (in addition to broad cultures of tissue for bacteria, mycobacteria, anaerobes, and fungi) may be helpful. For example, granulomatous inflammation suggests mycobacterial disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of septic bursitis includes cellulitis, crystalline bursitis (eg, gout or pseudogout), acute arthritis, and acute hemobursa.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cellulitis &mdash; Cellulitis may precede or accompany septic bursitis [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/37\">",
"       37",
"      </a>",
"      ]. Distinguishing cellulitis with and without bursitis depends on skilled palpation, or in some cases by demonstrating or excluding a fluid collection using ultrasonography for superficial and CT or MRI if deep bursal involvement is suspected. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"       \"Cellulitis and erysipelas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Crystal-induced bursitis &mdash; Periarticular inflammation may occur in patients with tophaceous gout, or less commonly pseudogout. A history of prior episodes of crystal-associated inflammation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the finding of crystals in the bursal fluid is suggestive. Concomitant gouty and septic bursitis may occur. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=see_link\">",
"       \"Clinical manifestations and diagnosis of gout\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=see_link\">",
"       \"Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute monoarthritis &mdash; Marked limitation of movement of the joint is a hallmark of acute monoarthritis. If present, a joint effusion is also suggestive of acute monoarthritis. However, effusions may be present in the knee in some patients with prepatellar or infrapatellar septic bursitis. If there is any doubt about a possible simultaneously occurring acute arthritis, the joint must be aspirated, preferably through clinically uninvolved skin, to minimize the risk of introducing infection [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2\">",
"       2",
"      </a>",
"      ]. Etiologies include rheumatoid or psoriatic arthritis, reactive arthritis, and ankylosing spondylitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=see_link\">",
"       \"Evaluation of the adult with monoarticular pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemobursa &mdash; Acute bleeding may cause tense swelling, pain, and tenderness with signs of inflammation. Attempted aspiration may not yield significant blood or fluid as the clotted blood can not be withdrawn through even a large gauge needle. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"       \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonseptic bursitis &mdash; It may be impossible to distinguish severe nonseptic noncrystalline bursitis from septic bursitis at the initial visit. The absence of fever, peripheral blood leukocytosis, crystals or bacteria in the bursal fluid when examined by polarizing microscopy and Gram stain, respectively, does not exclude septic bursitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=see_link\">",
"       \"Bursitis: An overview of clinical manifestations, diagnosis, and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patellar osteomyelitis &mdash; This is a rare but important diagnosis, and requires longer antibiotic courses. Operative treatment may be indicated for such infections [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/38\">",
"       38",
"      </a>",
"      ]. This should be considered in settings of relapsing &ldquo;bursitis.&rdquo;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of septic bursitis requires appropriate antibiotics, optimally guided by identification of the organism and antibiotic sensitivity testing, in combination with adequate drainage of infected bursal fluid. Initial antibiotic selection is guided by knowledge of common pathogens (most often staphylococcal and streptococcal spp) and by Gram stain results. Daily closed needle aspiration usually suffices for drainage of superficially located bursae. Surgical or catheter drainage may be needed for complicated septic bursitis at superficial sites and for deep bursal infection.",
"   </p>",
"   <p>",
"    Indications for hospitalization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intravenous antibiotic therapy for septic bursitis include the presence of fulminant local infection, evidence for systemic toxicity, or infection in an immunocompromised patient (eg, immunosuppressive drug treatment or neutropenia).",
"   </p>",
"   <p>",
"    Prophylaxis against tetanus may be indicated in cases of bursitis due to tetanus-prone trauma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"     \"Tetanus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Initial antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted, more than 80 percent of cases of septic bursitis are caused by S. aureus and other gram-positive organisms; however, the Gram stain is positive in only two-thirds of these instances [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2\">",
"     2",
"    </a>",
"    ]. If the Gram stain reveals no organisms, then one of the following approaches that are based on the severity of the inflammation and host factors, and provide adequate coverage for community-acquired staphylococcal and streptococcal infection may be appropriate (initial empiric therapy is modified, if necessary, based upon culture and antibiotic sensitivity testing results):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Mild inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If inflammation is mild, and the patient is reliable, not immunosuppressed or diabetic, and can be contacted once culture results are available, then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"     dicloxacillin",
"    </a>",
"    (dosed at 500 mg orally four times daily) or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (if penicillin allergic) may be appropriate first-line therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    are appropriate in regions with high rates of soft tissue infection due to MRSA. In vitro rates of susceptibility to clindamycin are higher among community-acquired MRSA than they are among healthcare-acquired MRSA, although there is variation by geographic region [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'High risk for MRSA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Severe inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If severe inflammation is present, or the patient is immunocompromised or unreliable, then intravenous (IV) antibiotic treatment is recommended.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily in two divided doses, assuming normal renal function) is increasingly used as initial empiric therapy followed by a change in antibiotics (if appropriate) based on culture and sensitivity testing results. Minimizing the duration of vancomycin use may reduce the risk of selection of vancomycin resistant enterococci or staphylococci.",
"   </p>",
"   <p>",
"    Administering IV antibiotics typically requires hospitalization, although a study of 118 patients with olecranon septic bursitis demonstrated successful treatment with sequential intravenous therapy administered via a home parenteral therapy program followed by oral therapy and drainage in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/6\">",
"     6",
"    </a>",
"    ]. The most common antibiotic regimen was sequential intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    (for a median of 4 days) followed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    orally (for a median of 8 days); sixty patients (51 percent) required a drainage procedure and only one patient required admission to hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     High risk for MRSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection should receive empiric therapy with an antimicrobial agent that has activity against MRSA (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a series of 12 community-acquired septic arthritis cases, 6 had MRSA (50 percent), 4 had methicillin-susceptible S. aureus (33 percent), and one each had Streptococcus pneumoniae, Enterococcus faecalis, and Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/40\">",
"     40",
"    </a>",
"    ]. These data suggest that a higher prevalence of community-acquired MRSA should be expected in septic bursitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Immunosuppressed host",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressed patients should be given broad-spectrum coverage that includes both anti-MRSA and anti-pseudomonal antibiotics while awaiting culture data. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duration of antibiotic therapy should be determined by the clinical response, culture results, and general health of the host. Many cases are treated for two to three weeks. One prospective study including 25 patients demonstrated that the length of time necessary to achieve sterility with antibiotic therapy (an average of four days) correlated with the duration of symptoms prior to diagnosis (ie, longer duration of symptoms was associated with delayed response) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/41\">",
"     41",
"    </a>",
"    ]. When antibiotic therapy was continued for five additional days after documented culture sterility, all patients in the trial were cured (average follow-up period of 6.8 months).",
"   </p>",
"   <p>",
"    In a subsequent retrospective study including 343 episodes of severe infectious bursitis (237 olecranon and 106 patellar) requiring inpatient care and bursectomy, Staphylococcus aureus was the predominant among the 256 cases with an identifiable pathogen (85 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/16\">",
"     16",
"    </a>",
"    ]. Surgery was performed in 312 cases (91 percent); 142 patients underwent one-stage bursectomy and closure and 146 patients underwent two-stage bursectomy. All received antibiotics for a median duration of 13 days (median duration of intravenous antibiotics was 3 days); cure was achieved in 85 percent of cases. There was no association between cure and the total duration of antibiotic therapy. Therefore, the authors conclude that adjuvant antibiotic therapy might be limited to seven days in non-immunosuppressed patients, though patients who do not undergo early drainage may need longer courses of antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical experience suggests that treating septic bursitis with antibiotics alone is often inadequate. Adequate drainage can usually be achieved without surgical intervention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superficial bursae can often be adequately drained using daily needle aspiration. Patients who fail to respond to intravenous antibiotics and percutaneous aspiration of the bursa may require surgical drainage or bursectomy.",
"     </li>",
"     <li>",
"      Deep bursae are more difficult to drain by repeated needle aspiration. For these sites surgical approaches or imaging-guided indwelling catheter placement are alternative approaches [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/33,34\">",
"       33,34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Repeated aspirations should be performed until the bursal fluid is sterile or no longer accumulates. An indwelling catheter may be withdrawn once the quantity of drainage has significantly decreased and only a small amount (eg, &lt;5",
"    <span class=\"nowrap\">",
"     mL/day)",
"    </span>",
"    or no drainage is noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Indication for surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suggested indications for surgical intervention for acute septic bursitis include inability to drain the bursa adequately via needle aspiration or catheter placement, presence of a foreign body, or adjacent skin or soft tissue infection requiring debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2,10\">",
"     2,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective study of adult patients with 343 cases of infectious olecranon and patellar bursitis who underwent early drainage noted that the duration of antibiotic therapy could be shortened; patients who do not undergo early drainage may need longer courses of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Open debridement can be complicated by skin necrosis and wound breakdown, in addition to scar sensitivity and a prolonged recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/42\">",
"     42",
"    </a>",
"    ]. In one series of eight patients who underwent endoscopic bursectomy for the treatment of septic pre-patellar bursitis, no recurrences, reports of tenderness or hypoaesthesia around the wound, wound complications, or skin necrosis were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Recurrent infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;If septic bursitis recurs following discontinuation of antibiotic treatment, another more prolonged course of antibiotics is generally tried before resorting to surgery. Following the first relapse, if there is subsequent recurrence of infection, or persistence of a thick bursal synovium, consideration should be given to total bursal excision during a quiescent phase of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/2\">",
"     2",
"    </a>",
"    ]. In one series, immunosuppression significantly increased the risk of recurrent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33256/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Preventing recurrent septic bursitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients whose occupations or leisure activities put them at increased risk of recurrent superficial bursitis may benefit from use of kneeling pads (during activities that predispose to prepatellar or infrapatellar bursitis) or elbow pads.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?3/23/3443?source=see_link\">",
"       \"Patient information: Bursitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=see_link\">",
"       \"Patient information: Bursitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superficial bursae (eg, olecranon and prepatellar) are predisposed to direct inoculation related to trauma while septic deep bursitis (eg, trochanteric or iliopsoas), unless iatrogenically inoculated, is typically due to hematogenous or contiguous spread of infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain and peribursal erythema, warmth, and an effusion are typical presenting features of superficial septic bursitis. Pain, tenderness, and restricted joint motion may indicate septic deep bursitis, with or without associated septic arthritis. Fever, peripheral blood leukocytosis, neutrophilia, and a shift to immature forms may be noted. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staphylococcus aureus is the causative organism in more than 80 percent of cases. Streptococci of various species are the next most commonly reported cause. Less commonly reported organisms causing acute septic bursitis include: coagulase-negative staphylococci, Enterococcus, Escherichia coli, Pseudomonas aeruginosa, and anaerobes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of septic bursitis is suggested by the clinical presentation and confirmed by culture of fluid from the affected bursa (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above). Aspiration yields fluid for culture, cell count, white blood cell differential, Gram stain, and crystal analysis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bursal fluid analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging with ultrasonography, magnetic resonance imaging (MRI), or computed tomography (CT) scanning is necessary to assess for the presence of deep bursal effusions. Ultrasonography or CT scanning are used to guide aspiration of deep bursae. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The range of bursal fluid nucleated cell counts in septic bursitis is wide and the best threshold value is uncertain, counts greater than 2000",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      are often found in septic bursal fluid. Gram stain results are most valuable when an organism is identified, and cannot be relied upon to rule out septic bursitis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bursal fluid analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of septic bursitis includes: cellulitis, crystal-induced bursitis, monoarthritis, hemobursa, and nonseptic bursitis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of septic bursitis requires appropriate antibiotics, optimally guided by identification of the organism and antibiotic sensitivity, in combination with adequate drainage of infected bursal fluid. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial antibiotic therapy for patients with suspected superficial septic bursitis depends primarily upon the severity of the inflammation, with consideration of host factors, the microbiology of soft tissue infections in the community (ie, local rates of MRSA), and care setting where the patient presents. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Initial antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mild inflammation &mdash; For the patient with mild inflammation who is not immunosuppressed or diabetic and can be relied upon to return if bursitis worsens, we suggest use of an oral antibiotic with antistaphylococcal activity (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/11/3253?source=see_link\">",
"       Dicloxacillin",
"      </a>",
"      (500 mg four times daily) or a second generation cephalosporin are typically chosen if the risk of MRSA is low. Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      is suggested for penicillin allergic patients and for patients at increased risk of MRSA infection; some isolates of MRSA are resistant or have inducible resistance. Oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , as used for skin and soft tissue infections, is another alternative if MRSA is suspected to be the causative agent.",
"     </li>",
"     <li>",
"      Severe inflammation &mdash; If severe inflammation is present or the patient is immunocompromised or unreliable, then we recommend initial intravenous (IV) antibiotics that provide antistaphylococcal coverage (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In recognition of the increasing prevalence of MRSA and the inability to predict from clinical features which patients have MRSA infection, we typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily in two divided doses, assuming normal renal function) followed by a change (if appropriate) to another antibiotic, when culture results and antibiotic sensitivity testing are available. If there is a history of anaphylaxis to penicillin, vancomycin can be continued and dosed according to renal function, with a goal trough of 15-20. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"       \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend repeated or continuous drainage of the infected bursa in the setting of severe inflammation that requires hospitalization (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Infected superficial bursae may be drained by repeated needle aspiration or surgical incision while infected deep bursae require catheter placement or open surgical drainage. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Drainage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Optimal duration of antibiotic treatment is uncertain. We typically treat for two to three weeks using a regimen of antibiotics that are likely to be effective based on the antibiotic sensitivity of the causative organism. Early surgical intervention may shorten the duration of antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8926548\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate Inc. would like to acknowledge Dr. Robert Sheon, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Sheon RP, Moskowitz RW, Goldberg VM. Soft Tissue Rheumatic Pain: Recognition, Management, Prevention, 3rd ed, Williams &amp; Wilkins, Baltimore 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/2\">",
"      Zimmermann B 3rd, Mikolich DJ, Ho G Jr. Septic bursitis. Semin Arthritis Rheum 1995; 24:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/3\">",
"      Valeriano-Marcet J, Carter JD, Vasey FB. Soft tissue disease. Rheum Dis Clin North Am 2003; 29:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/4\">",
"      Cea-Pereiro JC, Garcia-Meijide J, Mera-Varela A, Gomez-Reino JJ. A comparison between septic bursitis caused by Staphylococcus aureus and those caused by other organisms. Clin Rheumatol 2001; 20:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/5\">",
"      Garc&iacute;a-Porr&uacute;a C, Gonz&aacute;lez-Gay MA, Iba&ntilde;ez D, Garc&iacute;a-Pa&iacute;s MJ. The clinical spectrum of severe septic bursitis in northwestern Spain: a 10 year study. J Rheumatol 1999; 26:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/6\">",
"      Laupland KB, Davies HD, Calgary Home Parenteral Therapy Program Study Group. Olecranon septic bursitis managed in an ambulatory setting. The Calgary Home Parenteral Therapy Program Study Group. Clin Invest Med 2001; 24:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/7\">",
"      Stell IM, Gransden WR. Simple tests for septic bursitis: comparative study. BMJ 1998; 316:1877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/8\">",
"      Enzenauer RJ, Pluss JL. Septic olecranon bursitis in patients with chronic obstructive pulmonary disease. Am J Med 1996; 100:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/9\">",
"      Rubayi S, Montgomerie JZ. Septic ischial bursitis in patients with spinal cord injury. Paraplegia 1992; 30:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/10\">",
"      Small LN, Ross JJ. Suppurative tenosynovitis and septic bursitis. Infect Dis Clin North Am 2005; 19:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/11\">",
"      Drezner JA, Sennett BJ. Subacromial/subdeltoid septic bursitis associated with isotretinoin therapy and corticosteroid injection. J Am Board Fam Pract 2004; 17:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/12\">",
"      Ho G Jr, Tice AD, Kaplan SR. Septic bursitis in the prepatellar and olecranon bursae: an analysis of 25 cases. Ann Intern Med 1978; 89:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/13\">",
"      Canoso JJ, Yood RA. Reaction of superficial bursae in response to specific disease stimuli. Arthritis Rheum 1979; 22:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/14\">",
"      S&ouml;derquist B, Hedstr&ouml;m SA. Predisposing factors, bacteriology and antibiotic therapy in 35 cases of septic bursitis. Scand J Infect Dis 1986; 18:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/15\">",
"      Roschmann RA, Bell CL. Septic bursitis in immunocompromised patients. Am J Med 1987; 83:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/16\">",
"      Perez C, Huttner A, Assal M, et al. Infectious olecranon and patellar bursitis: short-course adjuvant antibiotic therapy is not a risk factor for recurrence in adult hospitalized patients. J Antimicrob Chemother 2010; 65:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/17\">",
"      Fischer PA, Kopp A, Massarotti EM. Anaerobic septic bursitis: case report and review. Clin Infect Dis 1996; 22:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/18\">",
"      Mathew SD, Tully CC, Borra H, et al. Septic subacromial bursitis caused by Mycobacterium kansasii in an immunocompromised host. Mil Med 2012; 177:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/19\">",
"      Gertner E. Chronic septic bursitis caused by dematiaceous fungi. Am J Orthop (Belle Mead NJ) 2007; 36:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/20\">",
"      Davis JM, Broughton SJ. Prepatellar bursitis caused by Brucella abortus. Med J Aust 1996; 165:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/21\">",
"      Guiral J, Reverte D, Carrero P. Iliopsoas bursitis due to Brucella melitensis infection--a case report. Acta Orthop Scand 1999; 70:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/22\">",
"      McDermott M, O'Connell B, Mulvihill TE, Sweeney EC. Chronic Brucella infection of the supra-patellar bursa with sinus formation. J Clin Pathol 1994; 47:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/23\">",
"      Rutten MJ, van den Berg JC, van den Hoogen FH, Lemmens JA. Nontuberculous mycobacterial bursitis and arthritis of the shoulder. Skeletal Radiol 1998; 27:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/24\">",
"      Kim RS, Lee JY, Jung SR, Lee KY. Tuberculous subdeltoid bursitis with rice bodies. Yonsei Med J 2002; 43:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/25\">",
"      Ihara K, Toyoda K, Ofuji A, Kawai S. Tuberculous bursitis of the greater trochanter. J Orthop Sci 1998; 3:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/26\">",
"      Friedman ND, Sexton DJ. Bursitis due to Mycobacterium goodii, a recently described, rapidly growing mycobacterium. J Clin Microbiol 2001; 39:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/27\">",
"      Crespo M, Pigrau C, Flores X, et al. Tuberculous trochanteric bursitis: report of 5 cases and literature review. Scand J Infect Dis 2004; 36:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/28\">",
"      Ornvold K, Paepke J. Aspergillus terreus as a cause of septic olecranon bursitis. Am J Clin Pathol 1992; 97:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/29\">",
"      Wall BA, Weinblatt ME, Darnall JT, Muss H. Candida tropicalis arthritis and bursitis. JAMA 1982; 248:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/30\">",
"      Ahbel DE, Alexander AH, Kleine ML, Lichtman DM. Protothecal olecranon bursitis. A case report and review of the literature. J Bone Joint Surg Am 1980; 62:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/31\">",
"      Torres HA, Bodey GP, Tarrand JJ, Kontoyiannis DP. Protothecosis in patients with cancer: case series and literature review. Clin Microbiol Infect 2003; 9:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/32\">",
"      Beltran J. MR imaging of soft-tissue infection. Magn Reson Imaging Clin N Am 1995; 3:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/33\">",
"      Ginesty E, Dromer C, Galy-Fourcade D, et al. Iliopsoas bursopathies. A review of twelve cases. Rev Rhum Engl Ed 1998; 65:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/34\">",
"      Manueddu CA, Hoogewoud HM, Balague F, Waldeburger M. Infective iliopsoas bursitis. A case report. Int Orthop 1991; 15:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/35\">",
"      Ho G Jr, Tice AD. Comparison of nonseptic and septic bursitis. Further observations on the treatment of septic bursitis. Arch Intern Med 1979; 139:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/36\">",
"      Goldin DS, Stangler DA, Canoso JJ. Rheumatoid subcutaneous bursitis. J Rheumatol 1981; 8:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/37\">",
"      Coste N, Perceau G, L&eacute;one J, et al. Osteoarticular complications of erysipelas. J Am Acad Dermatol 2004; 50:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/38\">",
"      Choi HR. Patellar osteomyelitis presenting as prepatellar bursitis. Knee 2007; 14:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/39\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/40\">",
"      Frazee BW, Fee C, Lambert L. How common is MRSA in adult septic arthritis? Ann Emerg Med 2009; 54:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/41\">",
"      Ho G Jr, Su EY. Antibiotic therapy of septic bursitis. Its implication in the treatment of septic arthritis. Arthritis Rheum 1981; 24:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/42\">",
"      Gendernalik JD, Sechriest VF 2nd. Prepatellar septic bursitis: a case report of skin necrosis associated with open bursectomy. Mil Med 2009; 174:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33256/abstract/43\">",
"      Dillon JP, Freedman I, Tan JS, et al. Endoscopic bursectomy for the treatment of septic pre-patellar bursitis: a case series. Arch Orthop Trauma Surg 2012; 132:921.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7650 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-3A23DB03CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33256=[""].join("\n");
var outline_f32_30_33256=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Superficial bursae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Deep bursae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bursa aspiration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bursal fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Additional Studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Initial antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Mild inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Severe inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - High risk for MRSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Immunosuppressed host",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Drainage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Indication for surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Recurrent infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Preventing recurrent septic bursitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8926548\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7650|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/18/8480\" title=\"picture 1\">",
"      Aspiration prepatellar bursa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/62/22496\" title=\"picture 2\">",
"      Aspiration olecranon bursa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7650|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/9/5275\" title=\"table 1\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14041?source=related_link\">",
"      Bursitis: An overview of clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/38/7785?source=related_link\">",
"      Clinical manifestations and diagnosis of calcium pyrophosphate crystal deposition disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4890?source=related_link\">",
"      Clinical manifestations and diagnosis of gout",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/43/16058?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of brucellosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14983?source=related_link\">",
"      Evaluation of elbow pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/14/28904?source=related_link\">",
"      Evaluation of the adult with monoarticular pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/48/28422?source=related_link\">",
"      Knee bursitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/27/44467?source=related_link\">",
"      Patient information: Bursitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/23/3443?source=related_link\">",
"      Patient information: Bursitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20360?source=related_link\">",
"      Synovial fluid analysis and the diagnosis of septic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_30_33257="Lung volume reduction surgery in COPD";
var content_f32_30_33257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lung volume reduction surgery in COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33257/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33257/contributors\">",
"     Fernando J Martinez, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33257/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33257/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33257/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33257/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/30/33257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emphysema is a form of chronic obstructive pulmonary disease (COPD) that is defined by abnormal and permanent enlargement of the airspaces distal to the terminal bronchioles and is associated with destruction of the alveolar walls. Emphysema causes dyspnea through airflow limitation, hyperinflation, and loss of gas exchanging surfaces in the lungs (also known as increased physiologic dead space).",
"   </p>",
"   <p>",
"    Lung volume reduction surgery (LVRS, also called reduction pneumoplasty or bilateral pneumectomy) is a surgical technique that may be beneficial for some patients with advanced emphysema who have poor control of their disease despite maximal medical therapy. LVRS entails reducing the lung volume by wedge excision of emphysematous tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The indications, contraindications, technique, and outcomes of LVRS will be reviewed here. The general management of chronic obstructive pulmonary disease, the evaluation and management of giant bullae, and the role of lung transplantation in end-stage emphysema are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=see_link\">",
"     \"Evaluation and medical management of giant bullae in COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=see_link\">",
"     \"Lung transplantation: General guidelines for recipient selection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE OF LVRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms by which LVRS might provide benefit are not known with certainty. It has been suggested that LVRS reduces the size mismatching between the hyperinflated lungs and the chest cavity, thereby restoring the outward circumferential pull on the bronchioles (ie, increasing elastic recoil) and improving expiratory airflow [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/2-8\">",
"     2-8",
"    </a>",
"    ]. As an example, in a study of 20 patients undergoing volume reduction surgery, 16 experienced an increase in elastic recoil [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/9\">",
"     9",
"    </a>",
"    ]. The patients with improved elastic recoil had a significantly greater increase in exercise capacity than the four without increased elastic recoil.",
"   </p>",
"   <p>",
"    Other postulated mechanisms for clinical benefit include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improvement in the mechanical function of the diaphragm and intercostal muscles by decreasing the functional residual capacity (FRC, the amount of air left in the lungs after exhalation of a tidal volume breath) and returning the diaphragm to a more normal curved and lengthened configuration (",
"      <a class=\"graphic graphic_figure graphicRef55440 \" href=\"UTD.htm?38/28/39373\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. In a study that examined the relative contribution of the thoracic (intercostal and scalene muscles) and abdominal (diaphragm) compartments to tidal volume breaths, an increase in the abdominal contribution was noted after LVRS, suggesting improved diaphragmatic function [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/12\">",
"       12",
"      </a>",
"      ]. In addition, improved synchrony of the diaphragm with other inspiratory muscles was noted, suggesting a reduction in respiratory muscle fatigue following LVRS.",
"     </li>",
"     <li>",
"      Improved left ventricular filling, end-diastolic dimension, and cardiac index due to decreased intrathoracic pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased central respiratory drive and ventilatory response to CO2, probably due to breathing at a lower lung volume. These changes would contribute to a decreased sensation of dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduction in lung volumes during exercise (ie, reduced dynamic hyperinflation), which is associated with reduced exertional dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36454?source=see_link\">",
"       \"Dynamic hyperinflation in patients with COPD\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NATIONAL EMPHYSEMA TREATMENT TRIAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several nonrandomized series and a few randomized trials have examined the efficacy of LVRS [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/15-22\">",
"     15-22",
"    </a>",
"    ]. The National Emphysema Treatment Trial (NETT) is the largest randomized trial of LVRS [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Trial design",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NETT trial compared the benefits of LVRS versus maximal medical therapy in 1218 patients with advanced emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"     22",
"    </a>",
"    ]. Following a baseline assessment, the patients underwent six to ten weeks of mandatory pulmonary rehabilitation and were then randomly assigned to LVRS or continued medical therapy. LVRS was performed by thoracotomy in 70 percent and by video-assisted thoracoscopy in 30 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Primary endpoints",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary endpoints of NETT were mortality and maximal exercise capacity at 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Within the first few months of starting the trial, a high risk of death (16 percent versus 0 percent for the medical therapy group) was identified in a subgroup of patients with a forced expiratory volume in one second (FEV1) of 20 percent predicted or less AND either homogeneous emphysema or a diffusing capacity for carbon monoxide (DLCO) that was 20 percent predicted or less [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with these characteristics were subsequently excluded from enrollment in NETT and LVRS is contraindicated in such patients.",
"   </p>",
"   <p>",
"    Among patients without these high-risk characteristics, the 30-day mortality rate was 2.2 percent in the LVRS group, compared with 0.2 percent in the medical therapy group (p&lt;0.001). At two years, total mortality among non high-risk patients did not differ between the LVRS and medical therapy groups (0.09 versus 0.10 deaths per person-year).",
"   </p>",
"   <p>",
"    Improvement in exercise capacity was defined as an increase in the maximal workload of more than 10 watts (W) at 24 months compared with the post-rehabilitation baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"     22",
"    </a>",
"    ]. Excluding the high-risk group, exercise capacity improved by more than 10 W in 16 percent of LVRS patients and 3 percent of medical therapy patients. In a separate analysis, the mean difference in maximal workload between the two groups was 10.9 W, favoring LVRS, with 10 W being the minimal clinically important difference in patients with severe emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, the effects of LVRS on exercise capacity were modest, but statistically and clinically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Subgroup analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subgroup analysis of NETT results was performed to assess whether particular patient characteristics would lead to differential risks or benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition to the high-risk group described above (also referred to as group A), the response of four additional subgroups to LVRS versus medical therapy was assessed. The subgroups were not prespecified, so the findings should be viewed with caution.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with upper lobe predominant emphysema and a low exercise capacity comprised 24 percent of all patients and were designated group B (",
"      <a class=\"graphic graphic_figure graphicRef74840 \" href=\"UTD.htm?21/56/22400\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54589 \" href=\"UTD.htm?36/22/37229\">",
"       table 1",
"      </a>",
"      ). Low exercise capacity was defined as less than the sex-specific 40th percentile (40 watts in men and 25 watts in women). Among this group, surgery did not affect 90 day mortality (2.9 versus 3.3 percent), but it reduced long-term mortality (risk ratio 0.47, p=0.005) (",
"      <a class=\"graphic graphic_figure graphicRef74840 \" href=\"UTD.htm?21/56/22400\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,25\">",
"       22,25",
"      </a>",
"      ]. Surgery was significantly more likely to lead to short-term and long-term improvement of exercise capacity and health-related quality of life.",
"     </li>",
"     <li>",
"      Patients with upper lobe predominant emphysema and high exercise capacity comprised 34 percent of all patients and were designated group C (",
"      <a class=\"graphic graphic_figure graphicRef74840 \" href=\"UTD.htm?21/56/22400\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54589 \" href=\"UTD.htm?36/22/37229\">",
"       table 1",
"      </a>",
"      ). Surgery did not impact the 90 day, short-term, or long-term mortality of this group (risk ratio 0.98, p=0.70) (",
"      <a class=\"graphic graphic_figure graphicRef74840 \" href=\"UTD.htm?21/56/22400\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,25\">",
"       22,25",
"      </a>",
"      ]. Surgery improved both exercise capacity and quality of life, and the improvements were sustained through three and four years of follow-up, respectively. High exercise capacity was defined as greater than the sex-specific 40th percentile (40 watts in men and 25 watts in women).",
"     </li>",
"     <li>",
"      Patients with non-upper lobe predominant emphysema and low exercise capacity comprised 12 percent of all patients and were designated group D (",
"      <a class=\"graphic graphic_figure graphicRef74840 \" href=\"UTD.htm?21/56/22400\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54589 \" href=\"UTD.htm?36/22/37229\">",
"       table 1",
"      </a>",
"      ). Among this group, LVRS slightly increased 90 day mortality, but did not affect mortality at 24 months (",
"      <a class=\"graphic graphic_figure graphicRef74840 \" href=\"UTD.htm?21/56/22400\">",
"       figure 2",
"      </a>",
"      ). Limited short-term improvement of exercise capacity was noted in this group; however, this advantage disappeared by the long-term follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,25\">",
"       22,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with predominantly non-upper lobe emphysema and high exercise capacity comprised 18 percent of all patients and were designated group E (",
"      <a class=\"graphic graphic_figure graphicRef74840 \" href=\"UTD.htm?21/56/22400\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54589 \" href=\"UTD.htm?36/22/37229\">",
"       table 1",
"      </a>",
"      ). Among this group, LVRS increased 90 day mortality (10.1 versus 0.9 percent), but did not affect long-term mortality (risk ratio 2.06, p=0.02) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,26,27\">",
"       22,26,27",
"      </a>",
"      ]. These patients had little short-term or long-term functional improvement with either type of therapy (",
"      <a class=\"graphic graphic_figure graphicRef74840 \" href=\"UTD.htm?21/56/22400\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef54589 \" href=\"UTD.htm?36/22/37229\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consideration for LVRS includes a thorough assessment of both cardiopulmonary function and the severity and distribution of emphysema. Testing typically includes pulmonary function tests, a six-minute walk test, arterial blood gas, electrocardiogram, echocardiogram with measurement of pulmonary artery pressures, a cardiopulmonary exercise test, and high resolution computed tomography (HRCT). The results of this assessment are used to determine the patient's candidacy for LVRS.",
"   </p>",
"   <p>",
"    HRCT has several roles in the evaluation of patients for possible LVRS: to confirm the presence of emphysema, quantitate the amount of lung affected, assess the anatomic distribution, and identify other conditions that may preclude LVRS. As an example, patients with a diffuse and homogeneous distribution of emphysema on HRCT are less likely to benefit from LVRS than patients with a heterogeneous distribution of emphysema, particularly those with upper lobe predominant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Subgroup analysis'",
"    </a>",
"    above.) In the NETT trial, HRCT identified other diseases that precluded LVRS on the scans of 174 patients (eg, pulmonary nodules, bronchiectasis, pleural disease, interstitial lung disease, giant bullae). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=see_link\">",
"     \"Diagnostic evaluation and management of the solitary pulmonary nodule\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=see_link\">",
"     \"Evaluation and medical management of giant bullae in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for LVRS in patients with emphysema are derived from the entry criteria for the National Emphysema Treatment Trial (NETT) and the results of that trial (",
"    <a class=\"graphic graphic_table graphicRef69501 \" href=\"UTD.htm?2/9/2205\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Appropriate candidates for LVRS typically have the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age less than 75 years [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe dyspnea despite optimal medical therapy and maximal pulmonary rehabilitation [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,29\">",
"       22,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Longer than six months of smoking cessation [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,29\">",
"       22,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Marked airflow obstruction on spirometry (FEV1 less than 45 percent predicted), consistent with the diagnosis of advanced COPD [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A diffusing capacity for carbon monoxide (DLCO) that is NOT less than 20 percent predicted [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lung volume measurements showing air trapping (eg, residual volume (RV) greater than 150 percent predicted, total lung capacity (TLC) greater than 100 percent predicted, an increased",
"      <span class=\"nowrap\">",
"       RV/TLC",
"      </span>",
"      ratio). An increased",
"      <span class=\"nowrap\">",
"       RV/TLC",
"      </span>",
"      ratio correlates with improved forced vital capacity (FVC) following LVRS [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/3,26,29,30\">",
"       3,26,29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Computed tomography findings of hyperinflation and heterogeneously distributed emphysema with some areas having better preserved lung tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/27,31-35\">",
"       27,31-35",
"      </a>",
"      ]. Patients with predominantly upper lung zone emphysema are more likely to benefit.",
"     </li>",
"     <li>",
"      Post-rehabilitation, a six-minute walk distance greater than 140 meters, but a low maximal achieved cycle ergometry (eg, less than 40 watts for men or 25 watts for women) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contraindications to LVRS for emphysema are derived from the exclusion criteria used for the NETT trial and from the results of that trial and other studies (",
"    <a class=\"graphic graphic_table graphicRef69501 \" href=\"UTD.htm?2/9/2205\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,29,36\">",
"     22,29,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age greater than 75 [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cigarette smoking within the prior six months [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A comorbid illness that would increase surgical mortality (eg, significant coronary heart disease, heart failure with a left ventricular ejection fraction less than 40 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,29\">",
"       22,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe cachexia or obesity (eg, 31.1",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      for men and 32.3",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      for women) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,29\">",
"       22,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inability to complete a 6 to 10 week program of pulmonary rehabilitation [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,29\">",
"       22,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A chest wall deformity, previous pleurodesis, or thoracotomy that would preclude surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,29\">",
"       22,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A chest HRCT scan that shows minimal emphysema or shows homogeneously distributed emphysematous changes without areas of preserved lung tissue, particularly if the FEV1 is less than 20 percent predicted [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Findings on HRCT that would be considered a contraindication for LVRS (eg, giant bulla, interstitial lung disease, pulmonary nodule) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Markedly abnormal alveolar gas exchange with a DLCO less than 20 percent of predicted, an arterial partial pressure of carbon dioxide (PaCO2) &gt; 60 mmHg, or an arterial partial pressure of oxygen (PaO2) &lt; 45 mmHg [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary hypertension (pulmonary artery systolic pressure greater than 45 mmHg, mean pulmonary artery pressure &gt;35 mmHg) [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with severe alpha-1 antitrypsin deficiency appear less likely to benefit from LVRS than patients with emphysema who are alpha-1 antitrypsin replete, although alpha-1 antitrypsin deficiency was not an absolute contraindication in the NETT trial. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16361?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of alpha-1 antitrypsin deficiency\", section on 'Lung volume reduction surgery'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Indications for unilateral LVRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral LVRS is sometimes performed instead of bilateral LVRS, when a patient has one or more of the following: unilateral or severely asymmetric emphysema, contralateral pleurodesis, contralateral thoracotomy, hemodynamic instability or massive air leak during the first side of a planned bilateral LVRS, or severe native lung hyperinflation after single lung transplantation for emphysema [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANESTHETIC MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced COPD who undergo LVRS are at increased risk for perioperative complications and require careful preoperative assessment and targeted adjustments to perioperative management [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative assessment typically includes ensuring that medical therapy for COPD is optimized and that comorbid illnesses (eg, coronary heart disease, heart failure) have been evaluated and treated, as necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/38\">",
"     38",
"    </a>",
"    ]. Preoperative management of patients with COPD is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link\">",
"     \"Evaluation of preoperative pulmonary risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=see_link\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"     \"Strategies to reduce postoperative pulmonary complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard monitoring during the procedure includes blood pressure, pulse oximetry, capnography, core temperature, and continuous electrocardiogram [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/39\">",
"     39",
"    </a>",
"    ]. Generally, an arterial line is placed for blood pressure monitoring and serial assessment of arterial blood gases [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/40\">",
"     40",
"    </a>",
"    ]. Central venous pressure monitoring is frequent, but not universal; pulmonary artery catheter placement has not been found to provide additional benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\", section on 'Respiratory effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antimicrobial prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimicrobial prophylaxis is administered within 60 minutes prior to the skin incision. The choice of antimicrobial therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of control measures to prevent surgical site infection\", section on 'Noncardiac thoracic surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;LVRS is typically performed under general anesthesia; short-acting anesthetic agents are preferred over longer-acting agents to enable early extubation. Intravenous agents are typically used for induction of anesthesia, as severe bullous disease may make the uptake and distribution of inhalational agents unpredictable [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/40\">",
"     40",
"    </a>",
"    ]. A thoracic epidural catheter is usually placed for administration of epidural anesthetic agents during",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    after surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=see_link&amp;anchor=H19#H19\">",
"     \"Evaluation of preoperative pulmonary risk\", section on 'Type of anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Single lung ventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;After induction of anesthesia, appropriate positioning and sterile draping, a double-lumen endotracheal tube (or other endotracheal tube that will allow isolation of ventilation to one lung) is placed to administer single lung ventilation to the nonoperative lung and to enable deflation of the operative lung [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/40\">",
"     40",
"    </a>",
"    ]. Correct placement of the endotracheal tube is confirmed bronchoscopically. Deflation of the operative lung may be slow due to the underlying obstructive airways disease and may require gentle suctioning and external pressure.",
"   </p>",
"   <p>",
"    During single lung ventilation, patients with advanced COPD may develop air trapping and hyperinflation, causing hemodynamic instability. Ventilatory techniques, such as using low tidal volumes, lower respiratory rates (eg, 5",
"    <span class=\"nowrap\">",
"     mL/kg),",
"    </span>",
"    and longer expiratory times (eg, an inspiratory to expiratory ratio of 1:3 or 1:5), can help to prevent this complication. Lowering minute ventilation in this way may lead to alveolar hypoventilation and elevation in the partial pressure of carbon dioxide (PaCO2). Accepting deliberate alveolar hypoventilation to mitigate auto-PEEP is known as permissive hypercapnic ventilation (PHV). With this technique, the pH is allowed to drop gradually into the range of 7.35 to 7.2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=see_link\">",
"     \"Permissive hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the strategies of permissive hypercapnia cause the pH to drop below 7.2, strategies such as a cautious increase in ventilatory rate, suctioning of airway secretions, optimizing muscle relaxation, and administering inhaled bronchodilator therapy, should help to improve alveolar ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a patient should develop hyperinflation and hemodynamic instability despite measures to minimize air trapping and auto-PEEP, transient disconnection of the endotracheal tube from the ventilator usually leads to resolution over several seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TECHNICAL ASPECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different surgical approaches and techniques for volume reduction are used to perform LVRS (37).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Thoracotomy versus thoracoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilateral LVRS may be performed through a median sternotomy, staged anterolateral thoracotomies, or video-assisted thoracoscopy. When bilateral LVRS is planned, most experts operate on the more severely affected side first. Unilateral LVRS is typically performed through a lateral thoracotomy or a video-assisted thoracoscopic approach.",
"   </p>",
"   <p>",
"    The decision about whether to perform LVRS via thoracotomy or thoracoscopy depends in large part on the surgical and institutional expertise [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/37\">",
"     37",
"    </a>",
"    ]. In a nonrandomized analysis of NETT data, morbidity and mortality were similar when LVRS was performed via thoracotomy or thoracoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/42\">",
"     42",
"    </a>",
"    ]. Thoracoscopic LVRS was associated with lower costs and shorter hospitalizations (9 versus 10 days) than median sternotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Volume reduction technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Volume reduction is generally achieved by making a series of wedge excisions in areas where the emphysematous changes are most marked. Typically, the amount of lung resected is 20 to 35 percent of each lung or as much as 60 percent of the total thoracic volume [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,37\">",
"     22,37",
"    </a>",
"    ]. The goal is to remove as much diseased lung as possible, while preserving the greatest amount of functioning lung.",
"   </p>",
"   <p>",
"    Buttressed staple sutures are typically employed to close the resultant defects and prevent air leaks. Bovine pericardial strips",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other materials (eg, polytetrafluoroethylene strips) may be used to buttress the suture line and reduce the incidence of postoperative air leaks [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/37,43-47\">",
"     37,43-47",
"    </a>",
"    ]. Less than 5 percent of patients in NETT had unbuttressed suture lines, so insufficient data is available to compare results with and without buttressed sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After completion of the wedge resections, two chest tubes are placed in the chest cavity, the clamp or bronchial blocker is removed from that side of the endotracheal tube, and mechanical ventilation is resumed to the deflated lung. A gradual reinflation is preferred to aggressive efforts at reinflation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laser ablation has been compared to stapler resection in patients undergoing unilateral LVRS [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Based on the observation of increased mortality in one study, an increase in the frequency of late pneumothorax in another study, and a decreased improvement in FEV1 at 6 months, the laser ablation technique has been abandoned [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/49,51\">",
"     49,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately postoperatively, patients are assessed for anemia due to excessive intraoperative blood loss, cardiac ischemia, electrolyte abnormalities, hypercapnia, hypoxemia, and inadequate lung reexpansion (eg, due to air leak, suboptimal function of chest tubes). If these factors are all acceptable, the patient is extubated. The majority of patients are extubated in the operating room to minimize the duration of positive pressure ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postextubation respiratory insufficiency can result from bronchoconstriction from the underlying COPD, atelectasis, pneumothorax, hypoventilation due to postoperative pain, or pneumonia. For awake patients with a rising PaCO2 despite prompt attention to these factors, noninvasive positive pressure ventilation may be used to avoid reintubation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the high proportion of patients with air leaks, careful attention to the proper function of the chest tubes is key to prevent development of a pneumothorax and consequent respiratory insufficiency. Brief kinking or blockage of a chest tube can lead to rapid accumulation of a pneumothorax and cardiopulmonary decompensation. A chest radiograph is obtained daily to confirm full lung reexpansion. Chest tubes are generally left in place until the lung is fully re-expanded and there is no evidence of air leak. The procedure for chest tube removal is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=see_link\">",
"     \"Placement and management of thoracostomy tubes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Management of postoperative pain usually involves a combination of regional and systemic agents to enable early mobilization of the patient and effective cough [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"     \"Management of postoperative pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link&amp;anchor=H17#H17\">",
"     \"Strategies to reduce postoperative pulmonary complications\", section on 'Postoperative strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of deep venous thrombosis and pulmonary embolism is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the 511 non-high-risk patients in the National Emphysema Treatment Trial (NETT) who underwent LVRS, the operative mortality rate was 6 percent, major pulmonary morbidity 30 percent, and major cardiovascular morbidity 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/53\">",
"     53",
"    </a>",
"    ]. The most common complications were reintubation (22 percent), arrhythmias (19 percent), pneumonia (18 percent), mechanical ventilation for more than two days (13 percent), persistent air leak for 30 days (12 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/54\">",
"     54",
"    </a>",
"    ]. Less common complications included intraoperative myocardial infarction, deep venous thrombosis, pulmonary embolism, and wound infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Air leak following LVRS is frequent. In the NETT trial, approximately 90 percent of patients had an air leak within 30 days of LVRS; the mean duration of air leak was seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/48\">",
"     48",
"    </a>",
"    ]. Patients with a low DLCO, upper lobe predominant emphysema, and pleural adhesions were more likely to have a persistent air leak and to experience prolonged leakage. In addition, Caucasian patients, patients using inhaled glucocorticoids, and patients with a low FEV1 tended to have a protracted duration of air leak.",
"   </p>",
"   <p>",
"    In a separate series, among 250 consecutive patients who underwent LVRS, persistent air leaks lasting over seven days occurred in 45 percent; re-exploration for air leaks or bleeding was needed in 3 and 1 percent, respectively. Postoperative reintubation and mechanical ventilation were necessary in 7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of LVRS on several long-term outcomes such as degree of dyspnea, quality of life, oxygenation, the BODE index, and cost effectiveness has been assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Dyspnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relief of dyspnea after LVRS has been examined in nonrandomized series and in the NETT trial as a secondary endpoint [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/15,22,55\">",
"     15,22,55",
"    </a>",
"    ]. In a series of 250 consecutive patients, dyspnea scores were improved over baseline in 88 percent, 79 percent, and 40 percent of patients at six months, one year, and five years following LVRS (",
"    <a class=\"graphic graphic_figure graphicRef55459 \" href=\"UTD.htm?9/25/9630\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the NETT trial described above, patients who underwent LVRS had a significantly greater improvement in dyspnea scores, as assessed by changes in the University of California San Diego (UCSD) Shortness of Breath Questionnaire, than those in the medical therapy group [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quality of life before and after LVRS has been examined in a number of studies (",
"    <a class=\"graphic graphic_table graphicRef54589 \" href=\"UTD.htm?36/22/37229\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/25,28,55,56\">",
"     25,28,55,56",
"    </a>",
"    ]. In a follow-up to the NETT trial described above, health-related quality of life was assessed using the St. George's Respiratory Questionnaire (SGRQ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients with upper lobe predominant disease and a low exercise capacity demonstrated improvement in SGRQ that lasted through five years of follow-up (p &lt; 0.001 years 1 to 3, p = 0.01 year 5). Patients with upper lobe predominant disease and a high exercise capacity also had an improved SGRQ, although the degree of significance was less. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Subgroup analysis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In a separate series of 250 patients who underwent LVRS at a single center, significant improvement in the quality of life was noted compared with values prior to surgery (",
"    <a class=\"graphic graphic_figure graphicRef51073 graphicRef54029 \" href=\"UTD.htm?17/0/17423\">",
"     figure 4A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unilateral LVRS has also been associated with improved quality of life in selected patients. As an example, in a series of 97 patients with asymmetric emphysema who underwent unilateral LVRS, significant improvement that persisted at least 36 months was noted in the Short Form-36 Quality of Life questionnaire [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Oxygenation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the NETT trial, resting PaO2 was more likely to increase and both treadmill and self-reported oxygen use (during rest, exercise, and sleep) were more likely to decrease with LVRS compared to medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/57\">",
"     57",
"    </a>",
"    ]. Improvement in oxygenation was predominantly seen in patients with upper lobe predominant emphysema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     BODE index",
"    </span>",
"    &nbsp;&mdash;&nbsp;Changes in the multidimensional index known as the BODE index have been assessed following LVRS (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?22/50/23329?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). In a retrospective cohort study of 186 patients with severe COPD who underwent LVRS, the postoperative, but not the preoperative BODE, correlated with five year survival [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/58\">",
"     58",
"    </a>",
"    ]. A decrease to a lower BODE score class was associated with reduced mortality (hazard ratio 0.50, 95% CI 0.38-0.66). In the NETT trial, patients undergoing LVRS exhibited a significant improvement in BODE compared with medically treated patients (",
"    <a class=\"graphic graphic_figure graphicRef71773 \" href=\"UTD.htm?41/39/42621\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/59\">",
"     59",
"    </a>",
"    ]. Furthermore, those who exhibited a one point decrease in BODE (improvement) after six months experienced a significantly better long term survival compared with those that experienced a one point rise (worsening) (",
"    <a class=\"graphic graphic_figure graphicRef82016 \" href=\"UTD.htm?29/37/30288\">",
"     figure 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35351?source=see_link&amp;anchor=H3#H3\">",
"     \"Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions\", section on 'BODE index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Cost-effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cost effectiveness of LVRS was assessed using the results of the NETT trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/22,60-64\">",
"     22,60-64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'National Emphysema Treatment Trial'",
"    </a>",
"    above.) Not including high-risk patients, the cost-effectiveness of LVRS versus medical therapy was $140,000 per quality-adjusted life-year (QALY) gained (95% confidence interval, $40,155 to $239,359) at 5 years, and was projected to be $54,000 per QALY gained at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/64\">",
"     64",
"    </a>",
"    ]. Thus, LVRS is substantially more costly than medical therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     LVRS AND LUNG TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When emphysema is advanced, both LVRS and lung transplantation are often considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Comparison",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective series compared functional outcomes (pulmonary function tests, arterial blood gas analysis, six-minute walk distance) in 33 patients who underwent LVRS versus 39 patients who had single lung transplantation and 27 patients who had bilateral sequential lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/65\">",
"     65",
"    </a>",
"    ]. The patients were evaluated before the operation and at 3, 6, and 12 months after surgery. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean FEV1 improved by 79 percent at six months and 82 percent at 12 months in the LVRS group, 231 and 212 percent in the single lung transplant group, and 498 and 518 percent in the bilateral lung transplant group (",
"      <a class=\"graphic graphic_figure graphicRef69230 \" href=\"UTD.htm?16/51/17213\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The six-minute walk distance at six months after surgery improved by 28 percent in the LVRS group, 47 percent in the single lung transplant recipients, and 79 percent in the bilateral lung transplant recipients (",
"      <a class=\"graphic graphic_figure graphicRef54892 \" href=\"UTD.htm?35/11/36029\">",
"       figure 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      All lung transplant recipients required supplemental oxygen before surgery, whereas none needed oxygen at rest or during exercise after the transplant. Eighty-eight percent of the patients who underwent LVRS required oxygen before surgery, and only 5.5 percent were oxygen-dependent during exercise and none at rest after LVRS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, while LVRS results in substantial improvements, single and bilateral lung transplantation result in superior lung function. Interpretation of these results must be cautious given the retrospective nature of the study and the baseline differences in age and pulmonary physiology between the groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Bridging procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo LVRS are not automatically excluded from undergoing lung transplantation. Limited experience with patients who initially undergo LVRS suggests that subsequent successful transplantation is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. In one prospective study, LVRS prior to lung transplantation improved symptoms and lung function enough to delay lung transplantation for a median of 33 months in 14 patients, while not impairing recovery or survival after transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33257/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     BRONCHOSCOPIC LUNG VOLUME REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung volume reduction surgery (LVRS) is associated with significant perioperative mortality, even when performed thoracoscopically. Bronchoscopic lung volume reduction (bLVR) is an emerging technique that may allow clinicians to reduce lung volume via a flexible fiberoptic bronchoscope and eliminate the need for surgery. Bronchoscopic lung volume reduction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13800?source=see_link\">",
"     \"Emerging therapies for COPD: Bronchoscopic treatment of emphysema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung volume reduction surgery (LVRS), also called reduction pneumoplasty, is a surgical technique that involves reducing the lung volume by multiple wedge excisions in areas where emphysematous changes are most marked. Typically, the amount of tissue resected is 20 to 35 percent of the volume of each lung. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LVRS modestly improves spirometry, lung volumes, exercise capacity, dyspnea, and quality of life and may improve long-term survival among highly selected patients. Certain clinical features appear to influence the degree of risk and benefit. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'National Emphysema Treatment Trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential complications of LVRS include persistent air leak, intraoperative myocardial infarction, reintubation, prolonged mechanical ventilation, pneumonia, wound infection, arrhythmias, deep venous thrombosis, pulmonary embolism, and death. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend NOT performing LVRS in high-risk patients (forced expiratory volume in one second (FEV1) of 20 percent predicted or less and either a diffusing capacity (DLCO) of 20 percent predicted or less or homogeneous emphysema on chest computed tomography) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'National Emphysema Treatment Trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have advanced emphysema that is upper lobe predominant, who have a low post-rehabilitation exercise tolerance despite maximal medical therapy for COPD, and who meet the inclusion criteria established by NETT, we suggest performing LVRS rather than continuing with medical therapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For all other patients with advanced emphysema, the decision to perform LVRS should be made on a case-by-case basis, with careful consideration of the patient's values and preferences. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'National Emphysema Treatment Trial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with severe alpha-1 antitrypsin deficiency appear less likely to benefit from LVRS than patients with emphysema who are alpha-1 antitrypsin replete. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16361?source=see_link&amp;anchor=H14#H14\">",
"       \"Treatment of alpha-1 antitrypsin deficiency\", section on 'Lung volume reduction surgery'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with advanced COPD are at increased risk for perioperative complications. All patients being considered for LVRS require careful preoperative assessment to ensure that medical therapy for COPD has been optimized and that any co-morbid illnesses have been identified and treated, as needed. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Preoperative evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of whether to perform LVRS via thoracotomy or thoracoscopy is usually based on the surgical and institutional expertise and preference. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Thoracotomy versus thoracoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients are extubated in the operating room. Management of postoperative pain usually involves a combination of regional and systemic agents to enable early mobilization of the patient and effective cough. Due to the high frequency of air leaks, careful attention to the proper function of the chest tubes is essential. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Postoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LVRS does not automatically exclude a patient from undergoing lung transplantation. Limited experience with patients who initially undergo LVRS suggests that subsequent successful transplantation is possible. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'LVRS and lung transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/1\">",
"      BRANTIGAN OC, MUELLER E, KRESS MB. A surgical approach to pulmonary emphysema. Am Rev Respir Dis 1959; 80:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/2\">",
"      Fessler HE, Permutt S. Lung volume reduction surgery and airflow limitation. Am J Respir Crit Care Med 1998; 157:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/3\">",
"      Fessler HE, Scharf SM, Ingenito EP, et al. Physiologic basis for improved pulmonary function after lung volume reduction. Proc Am Thorac Soc 2008; 5:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/4\">",
"      Ingenito EP, Loring SH, Moy ML, et al. Interpreting improvement in expiratory flows after lung volume reduction surgery in terms of flow limitation theory. Am J Respir Crit Care Med 2001; 163:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/5\">",
"      Ingenito EP, Loring SH, Moy ML, et al. Comparison of physiological and radiological screening for lung volume reduction surgery. Am J Respir Crit Care Med 2001; 163:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/6\">",
"      Martinez FJ, de Oca MM, Whyte RI, et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/7\">",
"      Keller CA, Ruppel G, Hibbett A, et al. Thoracoscopic lung volume reduction surgery reduces dyspnea and improves exercise capacity in patients with emphysema. Am J Respir Crit Care Med 1997; 156:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/8\">",
"      Sciurba FC. Early and long-term functional outcomes following lung volume reduction surgery. Clin Chest Med 1997; 18:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/9\">",
"      Sciurba FC, Rogers RM, Keenan RJ, et al. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med 1996; 334:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/10\">",
"      Lando Y, Boiselle PM, Shade D, et al. Effect of lung volume reduction surgery on diaphragm length in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/11\">",
"      Gorman RB, McKenzie DK, Butler JE, et al. Diaphragm length and neural drive after lung volume reduction surgery. Am J Respir Crit Care Med 2005; 172:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/12\">",
"      Bloch KE, Li Y, Zhang J, et al. Effect of surgical lung volume reduction on breathing patterns in severe pulmonary emphysema. Am J Respir Crit Care Med 1997; 156:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/13\">",
"      J&ouml;rgensen K, Houltz E, Westfelt U, et al. Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema. Chest 2003; 124:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/14\">",
"      Celli BR, Montes de Oca M, Mendez R, Stetz J. Lung reduction surgery in severe COPD decreases central drive and ventilatory response to CO2. Chest 1997; 112:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/15\">",
"      Yusen RD, Lefrak SS, Gierada DS, et al. A prospective evaluation of lung volume reduction surgery in 200 consecutive patients. Chest 2003; 123:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/16\">",
"      Lederer DJ, Thomashow BM, Ginsburg ME, et al. Lung-volume reduction surgery for pulmonary emphysema: Improvement in body mass index, airflow obstruction, dyspnea, and exercise capacity index after 1 year. J Thorac Cardiovasc Surg 2007; 133:1434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/17\">",
"      Pompeo E, Mineo TC. Two-year improvement in multidimensional body mass index, airflow obstruction, dyspnea, and exercise capacity index after nonresectional lung volume reduction surgery in awake patients. Ann Thorac Surg 2007; 84:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/18\">",
"      Geddes D, Davies M, Koyama H, et al. Effect of lung-volume-reduction surgery in patients with severe emphysema. N Engl J Med 2000; 343:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/19\">",
"      Hillerdal G, L&ouml;fdahl CG, Str&ouml;m K, et al. Comparison of lung volume reduction surgery and physical training on health status and physiologic outcomes: a randomized controlled clinical trial. Chest 2005; 128:3489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/20\">",
"      Miller JD, Berger RL, Malthaner RA, et al. Lung volume reduction surgery vs medical treatment: for patients with advanced emphysema. Chest 2005; 127:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/21\">",
"      Miller JD, Malthaner RA, Goldsmith CH, et al. A randomized clinical trial of lung volume reduction surgery versus best medical care for patients with advanced emphysema: a two-year study from Canada. Ann Thorac Surg 2006; 81:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/22\">",
"      Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/23\">",
"      National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. N Engl J Med 2001; 345:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/24\">",
"      Sutherland ER, Make BJ. Maximum exercise as an outcome in COPD: minimal clinically important difference. COPD 2005; 2:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/25\">",
"      Naunheim KS, Wood DE, Mohsenifar Z, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006; 82:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/26\">",
"      Ingenito EP, Evans RB, Loring SH, et al. Relation between preoperative inspiratory lung resistance and the outcome of lung-volume-reduction surgery for emphysema. N Engl J Med 1998; 338:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/27\">",
"      Hunsaker A, Ingenito E, Topal U, et al. Preoperative screening for lung volume reduction surgery: usefulness of combining thin-section CT with physiologic assessment. AJR Am J Roentgenol 1998; 170:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/28\">",
"      Hamacher J, B&uuml;chi S, Georgescu CL, et al. Improved quality of life after lung volume reduction surgery. Eur Respir J 2002; 19:54.",
"     </a>",
"    </li>",
"    <li>",
"     American Thoracic Society, European Respiratory Society. Standards for the diagnosis and management of patients with COPD. file://www.thoracic.org/clinical/copd-guidelines/index.php (Accessed on March 29, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/30\">",
"      Fessler HE, Scharf SM, Permutt S. Improvement in spirometry following lung volume reduction surgery: application of a physiologic model. Am J Respir Crit Care Med 2002; 165:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/31\">",
"      Cederlund K, Tyl&eacute;n U, Jorfeldt L, Aspelin P. Classification of emphysema in candidates for lung volume reduction surgery: a new objective and surgically oriented model for describing CT severity and heterogeneity. Chest 2002; 122:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/32\">",
"      Flaherty KR, Kazerooni EA, Curtis JL, et al. Short-term and long-term outcomes after bilateral lung volume reduction surgery : prediction by quantitative CT. Chest 2001; 119:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/33\">",
"      McKenna RJ Jr, Brenner M, Fischel RJ, et al. Patient selection criteria for lung volume reduction surgery. J Thorac Cardiovasc Surg 1997; 114:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/34\">",
"      Slone RM, Pilgram TK, Gierada DS, et al. Lung volume reduction surgery: comparison of preoperative radiologic features and clinical outcome. Radiology 1997; 204:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/35\">",
"      Washko GR, Hoffman E, Reilly JJ. Radiographic evaluation of the potential lung volume reduction surgery candidate. Proc Am Thorac Soc 2008; 5:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/36\">",
"      Martinez FJ, Chang A. Surgical therapy for chronic obstructive pulmonary disease. Semin Respir Crit Care Med 2005; 26:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/37\">",
"      Boasquevisque CH, Yildirim E, Waddel TK, Keshavjee S. Surgical techniques: lung transplant and lung volume reduction. Proc Am Thorac Soc 2009; 6:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/38\">",
"      DeCamp MM Jr, Lipson D, Krasna M, et al. The evaluation and preparation of the patient for lung volume reduction surgery. Proc Am Thorac Soc 2008; 5:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/39\">",
"      Hillier J, Gillbe C. Anaesthesia for lung volume reduction surgery. Anaesthesia 2003; 58:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/40\">",
"      Brister NW, Barnette RE, Kim V, Keresztury M. Anesthetic considerations in candidates for lung volume reduction surgery. Proc Am Thorac Soc 2008; 5:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/41\">",
"      Buettner AU, McRae R, Myles PS, et al. Anaesthesia and postoperative pain management for bilateral lung volume reduction surgery. Anaesth Intensive Care 1999; 27:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/42\">",
"      McKenna RJ Jr, Benditt JO, DeCamp M, et al. Safety and efficacy of median sternotomy versus video-assisted thoracic surgery for lung volume reduction surgery. J Thorac Cardiovasc Surg 2004; 127:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/43\">",
"      Fischel RJ, McKenna RJ Jr. Bovine pericardium versus bovine collagen to buttress staples for lung reduction operations. Ann Thorac Surg 1998; 65:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/44\">",
"      Hazelrigg SR, Boley TM, Magee MJ, et al. Comparison of staged thoracoscopy and median sternotomy for lung volume reduction. Ann Thorac Surg 1998; 66:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/45\">",
"      Swanson SJ, Mentzer SJ, DeCamp MM Jr, et al. No-cut thoracoscopic lung plication: a new technique for lung volume reduction surgery. J Am Coll Surg 1997; 185:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/46\">",
"      Vaughn CC, Wolner E, Dahan M, et al. Prevention of air leaks after pulmonary wedge resection. Ann Thorac Surg 1997; 63:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/47\">",
"      Moser C, Opitz I, Zhai W, et al. Autologous fibrin sealant reduces the incidence of prolonged air leak and duration of chest tube drainage after lung volume reduction surgery: a prospective randomized blinded study. J Thorac Cardiovasc Surg 2008; 136:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/48\">",
"      DeCamp MM, Blackstone EH, Naunheim KS, et al. Patient and surgical factors influencing air leak after lung volume reduction surgery: lessons learned from the National Emphysema Treatment Trial. Ann Thorac Surg 2006; 82:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/49\">",
"      Keenan RJ, Landreneau RJ, Sciurba FC, et al. Unilateral thoracoscopic surgical approach for diffuse emphysema. J Thorac Cardiovasc Surg 1996; 111:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/50\">",
"      Little AG, Swain JA, Nino JJ, et al. Reduction pneumonoplasty for emphysema. Early results. Ann Surg 1995; 222:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/51\">",
"      McKenna RJ Jr, Brenner M, Gelb AF, et al. A randomized, prospective trial of stapled lung reduction versus laser bullectomy for diffuse emphysema. J Thorac Cardiovasc Surg 1996; 111:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/52\">",
"      Meyers BF, Sultan PK, Guthrie TJ, et al. Outcomes after unilateral lung volume reduction. Ann Thorac Surg 2008; 86:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/53\">",
"      Naunheim KS, Wood DE, Krasna MJ, et al. Predictors of operative mortality and cardiopulmonary morbidity in the National Emphysema Treatment Trial. J Thorac Cardiovasc Surg 2006; 131:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/54\">",
"      DeCamp MM Jr, McKenna RJ Jr, Deschamps CC, Krasna MJ. Lung volume reduction surgery: technique, operative mortality, and morbidity. Proc Am Thorac Soc 2008; 5:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/55\">",
"      Ciccone AM, Meyers BF, Guthrie TJ, et al. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thorac Cardiovasc Surg 2003; 125:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/56\">",
"      Mineo TC, Ambrogi V, Pompeo E, et al. Impact of lung volume reduction surgery versus rehabilitation on quality of life. Eur Respir J 2004; 23:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/57\">",
"      Snyder ML, Goss CH, Neradilek B, et al. Changes in arterial oxygenation and self-reported oxygen use after lung volume reduction surgery. Am J Respir Crit Care Med 2008; 178:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/58\">",
"      Imfeld S, Bloch KE, Weder W, Russi EW. The BODE index after lung volume reduction surgery correlates with survival. Chest 2006; 129:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/59\">",
"      Martinez FJ, Han MK, Andrei AC, et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med 2008; 178:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/60\">",
"      Wise RA, Drummond MB. The role of NETT in emphysema research. Proc Am Thorac Soc 2008; 5:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/61\">",
"      Ault A. US government to pay for lung volume reduction surgery. Lancet 2003; 362:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/62\">",
"      Drazen JM, Epstein AM. Guidance concerning surgery for emphysema. N Engl J Med 2003; 348:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/63\">",
"      Ramsey SD, Berry K, Etzioni R, et al. Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. N Engl J Med 2003; 348:2092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/64\">",
"      Ramsey SD, Shroyer AL, Sullivan SD, Wood DE. Updated evaluation of the cost-effectiveness of lung volume reduction surgery. Chest 2007; 131:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/65\">",
"      Gaissert HA, Trulock EP, Cooper JD, et al. Comparison of early functional results after volume reduction or lung transplantation for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1996; 111:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/66\">",
"      Meyers BF, Yusen RD, Guthrie TJ, et al. Outcome of bilateral lung volume reduction in patients with emphysema potentially eligible for lung transplantation. J Thorac Cardiovasc Surg 2001; 122:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/67\">",
"      Nathan SD, Edwards LB, Barnett SD, et al. Outcomes of COPD lung transplant recipients after lung volume reduction surgery. Chest 2004; 126:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/68\">",
"      Tutic M, Lardinois D, Imfeld S, et al. Lung-volume reduction surgery as an alternative or bridging procedure to lung transplantation. Ann Thorac Surg 2006; 82:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33257/abstract/69\">",
"      Wisser W, Deviatko E, Simon-Kupilik N, et al. Lung transplantation following lung volume reduction surgery. J Heart Lung Transplant 2000; 19:480.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1430 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-E5FD8A8851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33257=[""].join("\n");
var outline_f32_30_33257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE OF LVRS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NATIONAL EMPHYSEMA TREATMENT TRIAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Trial design",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Primary endpoints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Subgroup analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Indications for unilateral LVRS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANESTHETIC MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antimicrobial prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Single lung ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TECHNICAL ASPECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Thoracotomy versus thoracoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Volume reduction technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      POSTOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LONG-TERM OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Dyspnea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Oxygenation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      BODE index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Cost-effectiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      LVRS AND LUNG TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Bridging procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      BRONCHOSCOPIC LUNG VOLUME REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1430\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1430|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/28/39373\" title=\"figure 1\">",
"      Lung volume and capacities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/56/22400\" title=\"figure 2\">",
"      LVRS survival curves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/25/9630\" title=\"figure 3\">",
"      Dyspnea post LVRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/23/9598\" title=\"figure 4A\">",
"      Patient satisfaction post LVRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/4/38989\" title=\"figure 4B\">",
"      SF-36 scores post LVRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/39/42621\" title=\"figure 5\">",
"      mBODE after LVRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/37/30288\" title=\"figure 6\">",
"      mBODE and survival postLVRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/51/17213\" title=\"figure 7\">",
"      FEV1 after LVRS or lung transplant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/11/36029\" title=\"figure 8\">",
"      Exercise after LVRS or lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1430|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/22/37229\" title=\"table 1\">",
"      Results bilateral LVRS in NETT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/9/2205\" title=\"table 2\">",
"      Indication contraind LVRS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?22/50/23329?source=related_link\" title=\"calculator 1\">",
"      Calculator: BODE Index for COPD survival prediction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/33/35351?source=related_link\">",
"      Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44537?source=related_link\">",
"      Diagnostic evaluation and management of the solitary pulmonary nodule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/38/36454?source=related_link\">",
"      Dynamic hyperinflation in patients with COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/30/13800?source=related_link\">",
"      Emerging therapies for COPD: Bronchoscopic treatment of emphysema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/60/8136?source=related_link\">",
"      Evaluation and medical management of giant bullae in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/8/1162?source=related_link\">",
"      Evaluation of preoperative pulmonary risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26953?source=related_link\">",
"      Lung transplantation: General guidelines for recipient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27127?source=related_link\">",
"      Permissive hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/62/16361?source=related_link\">",
"      Treatment of alpha-1 antitrypsin deficiency",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_30_33258="Pathogenesis of hepatic fibrosis";
var content_f32_30_33258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of hepatic fibrosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33258/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33258/contributors\">",
"     Scott L Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33258/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33258/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?32/30/33258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?32/30/33258/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?32/30/33258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrosis is a wound healing response in which damaged regions are encapsulated by an extracellular matrix or scar. It develops in almost all patients with chronic liver injury at variable rates depending in part upon the cause of liver disease and host factors [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. In contrast, for unclear reasons, patients with self-limited injury (such as fulminant hepatitis) do not develop scarring despite an abundance of fibrogenic stimuli, unless they go on to develop chronic injury.",
"   </p>",
"   <p>",
"    The composition of the hepatic scar is similar regardless of the cause of injury. Furthermore, hepatic fibrosis represents a paradigm for wound healing in other tissues, including skin, lung, and kidney, since it involves many of the same cell types and mediators.",
"   </p>",
"   <p>",
"    Fibrosis occurs earliest in regions where injury is most severe, particularly in chronic inflammatory liver disease due to alcohol or viral infection. As an example, pericentral injury is a hallmark of alcoholic hepatitis; the development of pericentral fibrosis (also known as sclerosing hyaline necrosis or perivenular fibrosis) is an early marker of likely progression to panlobular cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The development of fibrosis usually requires several months to years of ongoing injury. Two exceptions in adults are veno-occlusive disease and mechanical biliary obstruction, in which (for unclear reasons) fibrosis can progress more rapidly.",
"   </p>",
"   <p>",
"    While fibrosis is reversible in its initial stages, progressive fibrosis can lead to cirrhosis. The exact point when fibrosis becomes irreversible is incompletely understood. However, increasing evidence suggests that even early stages of cirrhosis may be reversible [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]. Furthermore, an understanding of the molecular mechanisms involved in fibrogenesis has a number of clinical implications, including the development of interventions designed to impede or reverse hepatic fibrosis, some of which are already available [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/12\">",
"     12",
"    </a>",
"    ]. Despite significant advances in understanding hepatic fibrosis and defining targets of therapy, there are no antifibrotic drugs yet approved for clinical use in patients with advanced liver disease.",
"   </p>",
"   <p>",
"    This topic review will discuss the mechanisms underlying hepatic fibrosis. A summary of the diagnosis of hepatic fibrosis and emerging therapies is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=see_link\">",
"     \"Emerging therapies for hepatic fibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTRACELLULAR MATRIX COMPOSITION OF THE NORMAL AND FIBROTIC LIVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracellular matrix (ECM) refers to a group of macromolecules that comprise the scaffolding of normal and fibrotic liver. These include collagens, non-collagen glycoproteins, matrix bound growth factors, glycosaminoglycans, proteoglycans, and matricellular proteins. A great deal of progress has been made in identifying new members of these families and in understanding how these molecules interact [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/13\">",
"     13",
"    </a>",
"    ]. In addition to providing the scaffolding of the liver, matrix molecules are now recognized to have a variety of other functions. As an example, some serve as transmembrane transducers of extracellular signals.",
"   </p>",
"   <p>",
"    Marked heterogeneity exists within different tissue regions in matrix composition with respect to the variety of isoforms within each class of molecules, their stoichiometry, and their intermolecular interactions. Furthermore, hybrid molecules have been identified that contain both collagenous and proteoglycan domains.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the normal liver, collagens types I, III, V, and XI (sometimes referred to as \"fibril-forming\" collagens) are principally found in the capsule, around large vessels, and in the portal triad, while only scattered fibrils containing types I and III collagen can be found in the subendothelial space. Smaller amounts of other collagens including types IV, VI, XIV (previously called \"undulin\"), and XVIII can also be found.",
"     </li>",
"     <li>",
"      Also present are glycoproteins and matricellular proteins including subendothelial deposits of fibronectin, laminin, tenascin, SPARC, and von Willebrand factor. The proteoglycans consist primarily of heparan sulfate proteoglycans such as perlecan, as well as small amounts of decorin, biglycan, fibromodulin, aggrecan, glypican, syndecan, and lumican [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As the liver becomes fibrotic, significant changes occur in the ECM quantitatively and qualitatively. The total collagen content increases 3- to 10-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/14\">",
"     14",
"    </a>",
"    ]. There is also a marked increase in the ECM to levels and composition typically seen in wound healing. These include an increase in fibril-forming collagens (ie, types I, III, and IV), some non-fibril forming collagens (types IV and VI), a number of glycoproteins (cellular fibronectin, laminin, SPARC, osteonectin, tenascin, and von Willebrand factor), proteoglycans, and glycosaminoglycans (perlecan, decorin, aggrecan, lumican, and fibromodulin) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/15\">",
"     15",
"    </a>",
"    ]. Particularly notable is a shift from heparan sulfate-containing proteoglycans to those containing chondroitin and dermatan sulfates. These processes represent a change in the type of ECM in subendothelial space from the normal low density basement membrane-like matrix to the interstitial type [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The replacement of the low density matrix with the interstitial type has consequences on the function of hepatocytes, hepatic stellate cells, and endothelial cells, in part explaining the synthetic and metabolic dysfunction observed in patients with advanced fibrosis. The high density matrix also activates hepatic stellate cells leading to the loss of hepatocyte microvilli and disappearance of endothelial fenestrations, which impairs transport of solutes from the sinusoid to the hepatocytes, thereby further contributing to the hepatocyte dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The liver responds to injury with angiogenic stimulation, with evidence of new blood vessel formation, sinusoidal remodeling, and pericyte (ie, stellate cell) amplification [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Thus, angiogenic mediators are involved, including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF) and their cognate receptors, as well as vasoactive mediators that include nitric oxide and carbon monoxide. Increased VEGF concentrations may be particularly important in progression of fibrosis in smokers who have hepatitis C [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Progressive accumulation of ECM composition provokes positive feedback pathways that further amplify fibrosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First, changes in membrane receptors, in particular integrins, sense altered matrix signals that provoke stellate cell activation and migration through focal adhesion disassembly [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/20-22\">",
"       20-22",
"      </a>",
"      ]. Matrix-provoked signals also engage membrane-bound GTP binding proteins, in particular Rho [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/23\">",
"       23",
"      </a>",
"      ] and Rac [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Second, activation of cellular matrix metalloproteases leads to release of fibrogenic and proliferative growth factors from matrix-bound reservoirs in the extracellular space [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/13,25\">",
"       13,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Third, the enhanced density of ECM leads to increasing matrix stiffness, which may stimulate stellate cell activation through integrin signaling [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/26\">",
"       26",
"      </a>",
"      ]. These experimental findings explain the increasing use of Fibroscan&reg; [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/27\">",
"       27",
"      </a>",
"      ] and MR elastography [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/28\">",
"       28",
"      </a>",
"      ], two clinical techniques which noninvasively assess hepatic stiffness as a reflection of ECM content. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=see_link\">",
"       \"Noninvasive assessment of hepatic fibrosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BIOLOGIC ACTIVITY OF EXTRACELLULAR MATRIX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Matrix alterations observed during fibrogenesis alter cellular behavior by processes involving cell membrane receptors. One of the best characterized are integrins, which are a large family of homologous membrane linker proteins that control several cellular functions including gene expression, growth, and differentiation. A variety of other cytokines and adhesion proteins involved in hepatic fibrogenesis have also been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Integrins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Integrins are composed of alpha and beta subunits whose ligands are matrix molecules rather than cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/29\">",
"     29",
"    </a>",
"    ]. In particular, integrin ligands contain an Arg-Gly-Asp tripeptide sequence. Several integrins and their downstream effectors have been identified in stellate cells, including alpha-1-beta-1, alpha-2-beta-1, alpha-5-beta-1, and alpha-6-beta-4. The common presence of Arg-Gly-Asp (RGD) with many integrin ligands has raised the possibility of using competitive RGD antagonists to block integrin-mediated pathways in fibrogenesis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=see_link\">",
"     \"Emerging therapies for hepatic fibrosis\"",
"    </a>",
"    .) More recent studies have identified alpha-V-beta-6 as a potentially important therapeutic target by virtue of its induction during cholestatic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Integrin signaling across the plasma membrane permits communication between the extracellular matrix and cytoskeleton. Signaling occurs in conjunction with the phosphorylation of several of intracellular substrates, which is typical of most transmembrane receptors. However, in addition to the \"outside-in\" signaling pathway, integrins can also signal in the opposite direction (ie, from the inside to the outside of the cell) thereby mediating cytoskeletal changes that can lead to altered conformation of extracellular matrix molecules such as fibronectin.",
"   </p>",
"   <p>",
"    Several integrin and non-integrin receptors have been described in situ on hepatocytes and non-parenchymal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/20,21,31-34\">",
"     20,21,31-34",
"    </a>",
"    ]. Upregulation of alpha-6-beta-1 and alpha-2-beta-1 receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/5\">",
"     5",
"    </a>",
"    ], both of which bind laminin, has been reported in experimental fibrosis. Studies have also defined the integrin phenotypes of isolated cell types from liver. In particular, stellate cells express integrin receptors for collagen and laminin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/20,31,32,35\">",
"     20,31,32,35",
"    </a>",
"    ], which may contribute to their activation and proliferation in response to deposition of these matrix components during injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other adhesion proteins and cell matrix receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing number of adhesion proteins and cell matrix receptors other than integrins have been characterized, including cadherins and selectins, which mediate interactions between inflammatory cells and the endothelial wall [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. As an example, upregulation of a tyrosine kinase receptor, discoidin domain receptor 2 (DDR2), has been observed during stellate cell activation leading to enhanced matrix metalloproteinase expression and cell growth [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/39\">",
"     39",
"    </a>",
"    ]. DDR2 is the only tyrosine kinase receptor whose ligand is an ECM molecule rather than a peptide ligand. Its upregulation may be a critical step toward perpetuating liver fibrosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Soluble growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extracellular matrix can also affect cell function indirectly by the release of soluble growth factors (cytokines). The soluble growth factors are controlled by local metalloproteinases (a family of zinc-dependent enzymes) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/40\">",
"     40",
"    </a>",
"    ]. The cytokines include PDGF, HGF, connective tissue growth factor (CTGF), TNFa, bFGF, and vascular endothelial cell growth factor (VEGF) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/13\">",
"     13",
"    </a>",
"    ]. Controlled release of these cytokines from the ECM is a key mechanism for regulating cytokine activity since it provides a local, accessible source of cytokines that can be regulated tightly through the actions of proteases and their inhibitors. In addition, ECM can regulate the activity of proteases through specific binding to collagens or fibronectins [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TGF-beta-1, derived from both paracrine and autocrine sources, remains the classic fibrogenic cytokine [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Signals downstream of TGF-beta converge upon Smad proteins, which fine-tune and enhance the effects of TGF-beta during stellate cell activation; Smads 2 and 3 are stimulatory whereas Smad7 is inhibitory [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/41,43,44\">",
"     41,43,44",
"    </a>",
"    ], and is antagonized by Id1 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/45\">",
"     45",
"    </a>",
"    ]. TGF-beta-1 also stimulates collagen transcription in stellate cells through a",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    - and",
"    <span class=\"nowrap\">",
"     C/EBP-beta-dependent",
"    </span>",
"    mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/46\">",
"     46",
"    </a>",
"    ]. The response of Smads in stellate cells evolves as injury becomes chronic, further enhancing fibrogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/43,47\">",
"     43,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CELLULAR SOURCES OF ECM IN NORMAL AND FIBROTIC LIVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major advance in the understanding of hepatic fibrosis has been the identification of the cellular sources of ECM. The hepatic stellate cell (previously called the lipocyte, Ito, fat-storing, or perisinusoidal cell) is the primary source of ECM in normal and fibrotic liver. In addition, related mesenchymal cell types from a variety of sources may have measurable contributions to total matrix accumulation, including classical portal fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/48-50\">",
"     48-50",
"    </a>",
"    ] (especially in biliary fibrosis), bone marrow derived cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/51\">",
"     51",
"    </a>",
"    ], as well as fibroblasts derived from epithelial-mesenchymal transition (EMT) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/52\">",
"     52",
"    </a>",
"    ]. EMT is a well characterized response of the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/52\">",
"     52",
"    </a>",
"    ] to injury but its role in liver injury has been less convincing.",
"   </p>",
"   <p>",
"    Hepatic stellate cells, located in subendothelial space of Disse between hepatocytes and sinusoidal endothelial cells, represent one-third of the non-parenchymal population or about 15 percent of the total number of resident cells in normal liver (",
"    <a class=\"graphic graphic_figure graphicRef53112 \" href=\"UTD.htm?39/44/40647\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/53\">",
"     53",
"    </a>",
"    ]. In normal liver, they are the principal storage site for retinoids (vitamin A metabolites), which accounts for 40 to 70 percent of retinoids in the body. Most of the retinoids are in the form of retinyl esters and are confined to cytoplasmic droplets. Stellate cells actually comprise a somewhat heterogeneous group of cells that are functionally and anatomically similar but differ in their expression of cytoskeletal filaments, their retinoid content, and in their potential for activation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Stellate cells with fibrogenic potential have been identified in locations other than the liver such as the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/57\">",
"     57",
"    </a>",
"    ]. Furthermore, remarkable plasticity of stellate cell phenotype has been documented in vivo and in culture, precluding a strict definition based only on cytoskeletal phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/34,58\">",
"     34,58",
"    </a>",
"    ]. Stellate cells with fibrogenic potential are not confined to liver, and have been identified in other organs such as the pancreas, where they contribute to desmoplasia in chronic pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/59\">",
"     59",
"    </a>",
"    ] and carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal and human studies have defined a process of changes within stellate cells that collectively are termed \"activation.\" During activation, stellate cells undergo a transition from a quiescent vitamin A-rich cell into proliferative, fibrogenic, and contractile myofibroblasts (",
"    <a class=\"graphic graphic_figure graphicRef66150 \" href=\"UTD.htm?18/15/18677\">",
"     figure 2",
"    </a>",
"    ). This change is characterized morphologically by enlargement of rough endoplasmic reticulum, diminution of vitamin A droplets, a ruffled nuclear membrane, appearance of contractile filaments, and proliferation. Cells with features of both quiescent and activated cells are sometimes referred to as \"transitional\" cells. Proliferation of stellate cells occurs predominantly in regions of greatest injury. Their function has been characterized in a variety of human diseases including alcoholic liver disease, viral hepatitis, hepatocellular carcinoma, vascular diseases, hematologic malignancy, biliary disease, mucopolysaccharidosis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    overdose, leishmaniasis, allograft rejection, and in drug abusers [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/61-65\">",
"     61-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sinusoidal endothelial cells are also an important contributor to early fibrosis. Similar to stellate cells, there is considerable heterogeneity of this cell type in normal and fibrotic liver [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/56\">",
"     56",
"    </a>",
"    ]. Endothelial cells from normal liver produce types III and IV collagen, laminin, syndecan, and fibronectin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. Increased expression of cellular isoforms of fibronectin by these cells is a key early event following acute liver injury because their appearance creates a microenvironment that activates stellate cells.",
"   </p>",
"   <p>",
"    Other cell types may also contribute to fibrosis. CD8+ lymphocytes are potentially profibrogenic cells based upon their ability to induce fibrogenesis after adoptive transfer from animals with liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Remarkably, very few studies have defined the cellular or matrix composition of congenital hepatic fibrosis, an entity whose pathogenesis is unclear. Current theories suggest that as in adults, congenital fibrosis represents a final common pathway of fetal hepatic injury, whether from biliary malformations, viral infections (especially cytomegalovirus) or other insult, with the stellate cell playing a significant role [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibrogenic cells in the liver derive not only from resident stellate cells, but also from portal fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/48,72,73\">",
"     48,72,73",
"    </a>",
"    ], and potentially from circulating fibrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/74\">",
"     74",
"    </a>",
"    ], bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/51\">",
"     51",
"    </a>",
"    ], and epithelial-mesenchymal cell transition [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/75\">",
"     75",
"    </a>",
"    ]. Portal fibroblasts may be particularly important in cholestatic liver diseases and ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/73\">",
"     73",
"    </a>",
"    ], in which paracrine interactions between cholangiocytes and fibroblasts involve both chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/76\">",
"     76",
"    </a>",
"    ] and extracellular nucleotides [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/77\">",
"     77",
"    </a>",
"    ]. Although controversial, progressive recruitment of bone marrow derived cells may occur over time, ultimately representing a significant fraction of the total fibrogenic population in more chronic injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DEGRADATION OF EXTRACELLULAR MATRIX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrosis reflects a balance between matrix production and degradation. The degradation of extracellular matrix is a key event in hepatic fibrosis. Early disruption of the normal hepatic matrix by matrix proteases hastens its replacement by scar matrix, which has deleterious effects on cell function. As a result, such degradation has been referred to as being \"pathologic\". On the other hand, resorption of excess matrix in patients with chronic liver disease provides the opportunity to reverse hepatic dysfunction and portal hypertension.",
"   </p>",
"   <p>",
"    An understanding of mechanisms involved in matrix remodeling has evolved significantly in the past several years. A critical element in matrix remodeling is a family of matrix-metalloproteinases (also known as matrixins). These are calcium-dependent enzymes that specifically degrade collagens and non-collagenous substrates [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/78\">",
"     78",
"    </a>",
"    ]. As a general rule, the matrix-metalloproteinases fall into five categories based upon their substrate specificity:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Interstitial collagenases (MMP-1, -8, -13), which degrade interstitial collagens",
"     </li>",
"     <li>",
"      Gelatinases (MMP-2, -9 and fibroblast activation protein), which generally degraded basement membrane collagens and denatured interstitial collagen",
"     </li>",
"     <li>",
"      Stromelysins (MMP-3, -7, -10, 11), which have a broad substrate range",
"     </li>",
"     <li>",
"      Membrane type (MMP-14, 15, -16, -17, -24, -25), which are primarily interstitial collagenases",
"     </li>",
"     <li>",
"      Metalloelastase (MMP-12), which degrades elastin",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Metalloproteinases are regulated at many levels, permitting their activity to be restricted to discrete regions within the pericellular environment. Inactive metalloproteinases can be activated through proteolytic cleavage by either membrane-type matrix metalloproteinase 1 (MT1-MMP) or plasmin, and inhibited by binding to specific inhibitors known as TIMPs (\"tissue inhibitors of metalloproteinases\"). As an example, MT1-MMP and TIMP-2 form a ternary complex with MMP-2, possibly including avb3 integrin, which is essential for optimal MMP-2 activity [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/78\">",
"     78",
"    </a>",
"    ]. Plasmin activity is controlled by its activating enzyme uroplasminogen activator (uPA) and a specific inhibitor, plasminogen activator inhibitor 1 (PAI-1), and can be stimulated by active transforming growth factor beta 1 (TGF-beta-1).",
"   </p>",
"   <p>",
"    Thus, collagenase activity reflects the relative amounts of activated metalloproteinases and their inhibitors, especially TIMPs. Other protease inhibitors (such as a2-macroglobulin) may also affect net degradative activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathologic matrix degradation",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Pathologic\" matrix degradation refers to the early disruption of the matrix of the normal space between hepatocytes and endothelial cells. Degradation occurs through the actions of at least four enzymes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Matrix metalloproteinase 2 (MMP2) (also called \"gelatinase\" or \"72 kDA type IV collagenase\") and MMP-9 (\"gelatinase B\" or \"92 kDa type IV collagenase\"), which degrade type IV collagen",
"     </li>",
"     <li>",
"      Membrane-type metalloproteinase-1 or -2, which activate latent MMP2",
"     </li>",
"     <li>",
"      Stromelysin-1, which degrades proteoglycans and glycoproteins, and also activates latent collagenases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stellate cells are the principal source of MMP-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/79,80\">",
"     79,80",
"    </a>",
"    ] and stromelysin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/81\">",
"     81",
"    </a>",
"    ]. Activation of latent MMP-2 may require interaction with hepatocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Markedly increased expression of MMP-2 is characteristic of cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/84\">",
"     84",
"    </a>",
"    ]. MMP-9 is secreted locally by Kupffer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/78\">",
"     78",
"    </a>",
"    ]. Disruption of the normal liver matrix is also a requirement for tumor invasion and desmoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failure to degrade the increased interstitial, or scar matrix is a major determinant of progressive fibrosis. Matrix metalloproteinase-1 (MMP-1) is the main protease that can degrade type I collagen, the principal collagen in fibrotic liver. However, sources of this enzyme are not as clearly established as for the type IV collagenases. Stellate cells express MMP-1 mRNA but little enzyme can be detected [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/86\">",
"     86",
"    </a>",
"    ]. More importantly, progressive fibrosis is associated with marked increases in TIMP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/87,88\">",
"     87,88",
"    </a>",
"    ] and TIMP-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/89\">",
"     89",
"    </a>",
"    ], leading to a net decrease in protease activity, and therefore more unopposed matrix accumulation. Stellate cells are the major source of these inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/90\">",
"     90",
"    </a>",
"    ]. Sustained TIMP-1 expression is emerging as a key reason for progressive fibrosis, and its diminution is an important prerequisite to allow for reversal of fibrosis (see below). Unique mechanisms of TIMP-1 regulation in stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/91\">",
"     91",
"    </a>",
"    ] offer the potential for selective inhibition of TIMP-1 expression in order to accelerate resorption of scar matrix in patients with liver disease.",
"   </p>",
"   <p>",
"    The cross-linking of collagen by lysyl oxidase and tissue transglutaminase, and the \"maturation\" of hepatic scar through the action of ADAMTS2 (A Disintegrin and Metalloproteinase with ThromboSpondin type repeats metalloproteinase with thrombospondin type I motif) may regulate hepatic fibrosis reversibility. In animal models, even advanced fibrosis is reversible, limited primarily by the extent of collagen cross-linking due to tissue transglutaminase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/92\">",
"     92",
"    </a>",
"    ]. As advanced fibrosis resolves, the micronodules typical of active cirrhosis dissolve, coalescing into macronodules [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/92\">",
"     92",
"    </a>",
"    ]. This finding correlates with clinical data demonstrating that increased septal thickness and smaller nodule size are significant predictors of poorer clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     STELLATE CELL ACTIVATION, THE CENTRAL EVENT IN HEPATIC FIBROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic stellate cell activation is the common pathway leading to hepatic fibrosis. Once they are activated, they release chemokines and other leukocyte chemoattractants while upregulating the expression of important inflammatory receptors such as ICAM-1, chemokine receptors, and mediators of lipopolysaccharide signaling.",
"   </p>",
"   <p>",
"    Activation consists of two major phases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiation (also called a \"preinflammatory stage\"), which refers to early changes in gene expression and phenotype that render the cells responsive to other cytokines and stimuli [",
"      <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/54\">",
"       54",
"      </a>",
"      ]. Initiation results mostly from paracrine stimulation.",
"     </li>",
"     <li>",
"      Perpetuation results from the effects of these stimuli on maintaining the activated phenotype and generating fibrosis. Perpetuation involves autocrine as well as paracrine loops.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Initiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest changes observed during stellate activation result from paracrine stimulation by all neighboring cell types, including sinusoidal endothelium, Kupffer cells, hepatocytes, and platelets. As noted above, early injury to endothelial cells stimulates production of cellular fibronectin, which has an activating effect on stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/69\">",
"     69",
"    </a>",
"    ]. Endothelial cells are also likely to participate in conversion of TGF-beta from the latent to active, profibrogenic form. Platelets are another important source of paracrine stimuli, including platelet derived growth factor (PDGF), TGF-beta-1, and epidermal growth factor (EGF) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/94\">",
"     94",
"    </a>",
"    ]. TGF-beta-1, derived from both paracrine and autocrine sources, is the best characterized and most potent fibrogenic cytokine.",
"   </p>",
"   <p>",
"    Kupffer cell infiltration and activation also contribute to stellate cell activation. Kupffer cells stimulate matrix synthesis, cell proliferation, and release of retinoids by stellate cells through the actions of cytokines (especially TGF-beta-1) and reactive oxygen",
"    <span class=\"nowrap\">",
"     intermediates/lipid",
"    </span>",
"    peroxides. On the other hand, activated Kupffer cells can also lead to stellate cell apoptosis by different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hepatocytes are also a potent source of fibrogenic lipid peroxides. Hepatocyte apoptosis following injury also promotes stellate cell initiation through a process mediated by Fas (a protein involved in causing apoptosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Apoptosis of parenchymal cells is also an important inflammatory stimulus [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/98\">",
"     98",
"    </a>",
"    ]. The response of stellate cells to apoptotic hepatocytes in part reflects the interaction of hepatocyte DNA with Toll-like receptor 9 (TLR9) expressed on stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/99\">",
"     99",
"    </a>",
"    ]. A profibrogenic response can also be elicited by hepatocyte apoptosis following disruption of the antiapoptotic mediator Bcl-xL and by Fas [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/96,100\">",
"     96,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, efforts to block hepatocyte apoptosis therapeutically are being developed as a potential antifibrotic strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/101\">",
"     101",
"    </a>",
"    ]. In contrast, selective stimulation of apoptosis in stellate cells by either TRAIL [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/102\">",
"     102",
"    </a>",
"    ], gliotoxin [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/103\">",
"     103",
"    </a>",
"    ], or proteasome inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/104\">",
"     104",
"    </a>",
"    ] is antifibrotic. While hepatocyte necrosis associated with lipid peroxidation is considered a classical inflammatory and fibrogenic stimulus, apoptosis, or programmed cell death, has also been implicated in the fibrogenic response. Apoptotic fragments released from hepatocytes are fibrogenic towards cultured stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/105\">",
"     105",
"    </a>",
"    ], and activate Kupffer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/106\">",
"     106",
"    </a>",
"    ] Also, Fas-mediated hepatocyte apoptosis in vivo in experimental animals is fibrogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cytochrome CYP2E1 may have an important role in the generation of reactive oxygen species that stimulates hepatic stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/107\">",
"     107",
"    </a>",
"    ]. Cultured hepatic stellate cells grown in the presence of a cell that expresses CYP2E1 (E47 cells) increase the production of collagen, an effect prevented in the presence of antioxidants or a CYP2E1 inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/107\">",
"     107",
"    </a>",
"    ]. These data suggest that the CYP2E1-derived reactive oxygen species are responsible for the increased collagen production. In similar experiments using co-cultured hepatic stellate and E47 cells, the addition of arachidonic acid plus ferric nitrilotriacetate (agents that potentiate oxidative stress) further induced collagen protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/108\">",
"     108",
"    </a>",
"    ]. These findings may help to explain the pathogenesis of liver injury in alcoholic liver disease since CYP2E1 is alcohol-inducible.",
"   </p>",
"   <p>",
"    As noted above, reactive oxygen species (ROS) are generated through lipid peroxidation from hepatocytes, macrophages, stellate cells, and other inflammatory cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]. In alcoholic or nonalcoholic steatohepatitis, ROS generation in hepatocytes results from induction of cytochrome P450 2E1 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/111,112\">",
"     111,112",
"    </a>",
"    ], leading to pericentral (zone 3) injury. Also, NADPH oxidase (NOX) mediates fibrogenic activation in hepatic stellate cells, as well as in Kupffer cells or resident liver macrophages through generation of oxidant stress [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/113\">",
"     113",
"    </a>",
"    ]. HCV as well as",
"    <span class=\"nowrap\">",
"     HCV/HIV",
"    </span>",
"    coinfection also produce oxidant stress molecules that amplify inflammation and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/114,115\">",
"     114,115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nitrosative stress from hepatocyte mitochondrial injury and induction of nitric oxide synthase 2(NOS2) may also be an overlooked pathway of liver injury [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. Hypoxia is typically also a component of the injury milieu and elicits fibrogenic and angiogenic signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The identification of TLR4, the receptor for bacterial lipopolysaccharide, on Kupffer cells and stellate cells introduces a role for the innate immune system in hepatic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/118\">",
"     118",
"    </a>",
"    ]. Furthermore, signaling by stellate cells in response to LPS and possibly endogenous ligands of TLR4 (eg, high-mobility group box 1 (HMGB1), biglycan and heparan sulfate) may be more important than in Kupffer cells in eliciting a fibrogenic response by downregulating BAMBI, a transmembrane suppressor of TGF-beta-1, which is the major fibrogenic cytokine in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/119\">",
"     119",
"    </a>",
"    ]. This finding correlates with evidence that specific single nucleotide polymorphisms of TLR4 contribute to the rate of fibrosis progression in HCV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/120\">",
"     120",
"    </a>",
"    ], thereby linking a genetic risk marker to disease pathogenesis.",
"   </p>",
"   <p>",
"    Direct effects of hepatotrophic viruses may also contribute to stellate cell activation. In particular, HCV proteins can activate stellate cells through several mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/121-123\">",
"     121-123",
"    </a>",
"    ], whereas accelerated fibrosis in chronic HBV may engage specific immune cell types, especially natural killer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/124\">",
"     124",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Gene regulation during stellate cell activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attention has focused on regulatory pathways that can respond quickly to injurious stimuli, either by activating or repressing gene transcription, by epigenetic regulation, or by posttranscriptional control.",
"   </p>",
"   <p>",
"    Among the many target genes of transcription factors described in stellate cells, those most comprehensively characterized include type I collagen (alpha 1 and alpha 2 chains), alpha-SMA, TGF-beta-1 and TGF-beta receptors, MMP-2, and TIMPs 1 and 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/125-128\">",
"     125-128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epigenetic regulation is a tightly controlled pathway that modulates stellate cell activation in part through induction of the molecules CBF1 and MeCP2 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/126,129,130\">",
"     126,129,130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    mRNA stabilization also contributes to increased gene expression during stellate cell activation. Specifically, there is a 16-fold increase in collagen alpha 1(I) mRNA stabilization during stellate cell activation due to interaction of a specific protein, alpha CP, to a specific sequence in the 3' untranslated region of the mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/131\">",
"     131",
"    </a>",
"    ], and also involving the interaction of a 120 kDa protein with the 5' stem-loop structure [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Perpetuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perpetuation of stellate cell activation involves at least seven discrete changes in cell behavior: proliferation, chemotaxis, fibrogenesis, contractility, matrix degradation, retinoid loss, and WBC chemoattractant and cytokine release. The net effect of these changes is to increase accumulation of extracellular matrix. As an example, proliferation and chemotaxis lead to increased numbers of collagen-producing cells as well as more matrix production per cell. Cytokine release by stellate cells can amplify the inflammatory and fibrogenic tissue responses, and matrix proteases may hasten the replacement of normal matrix with one typical of the wound \"scar\".",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Proliferation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet derived growth factor (PDGF) is the most potent stellate cell mitogen identified [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/133\">",
"     133",
"    </a>",
"    ]. Induction of PDGF receptors early in stellate cell activation increases responsiveness to this potent mitogen [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/134\">",
"     134",
"    </a>",
"    ]. A co-receptor, neuropilin-1, may enhance PDGF signaling at the cell membrane of stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/135\">",
"     135",
"    </a>",
"    ]. Downstream pathways of PDGF signaling have been carefully characterized in stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/136\">",
"     136",
"    </a>",
"    ]. In addition to proliferation, PDGF stimulates",
"    <span class=\"nowrap\">",
"     Na+/H+",
"    </span>",
"    exchange, providing a potential site for therapeutic intervention by blocking ion transport [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/137\">",
"     137",
"    </a>",
"    ]. Other compounds with mitogenic activity in stellate cells and a potential role in fibrogenesis include vascular endothelial cell growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/138\">",
"     138",
"    </a>",
"    ], thrombin and its receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/139,140\">",
"     139,140",
"    </a>",
"    ], EGF, TGFa, keratinocyte growth factor [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/141\">",
"     141",
"    </a>",
"    ] and bFGF [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/142\">",
"     142",
"    </a>",
"    ]. Signaling pathways for these and other mitogens have been greatly clarified in stellate cells, offering many potential sites for therapeutic intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/136,143\">",
"     136,143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelet-derived growth factor (PDGF) -C and -D isoforms have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/144\">",
"     144",
"    </a>",
"    ]. PDGF-D may be the most potent and physiologically relevant PDGF subunit in stellate cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/145\">",
"     145",
"    </a>",
"    ]. Furthermore, whereas both mice with transgenic expression of either PDGF-B [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/144\">",
"     144",
"    </a>",
"    ] or PDGF-C have hepatic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/138\">",
"     138",
"    </a>",
"    ], the PDGF-C transgenic animals also develop hepatocellular carcinoma (HCC) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/138\">",
"     138",
"    </a>",
"    ], mimicking the progression from fibrosis to cancer that occurs in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chemotaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stellate cells can migrate towards cytokine chemoattractants [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/146,147\">",
"     146,147",
"    </a>",
"    ], explaining in part why stellate cells align within inflammatory septae in vivo. These chemoattractants include PDGF [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/148,149\">",
"     148,149",
"    </a>",
"    ], MCP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/150\">",
"     150",
"    </a>",
"    ], and CXCR3 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to PDGF, adenosine blunts chemotaxis, thereby providing a counter-regulatory pathway that fixes cells at sites of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/152\">",
"     152",
"    </a>",
"    ]. Paradoxically, enhanced adenosine signaling may also contribute to alcoholic fibrosis by stimulating stellate cell fibrogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/153\">",
"     153",
"    </a>",
"    ], which not only represents a potential fibrogenic mechanism, but also may explain the protective effect of caffeine (which inhibits adenosine generation) reported in epidemiologic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Fibrogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most direct way that stellate cells influence fibrosis is by increasing matrix production and scar formation. The best-studied component of hepatic scar is collagen type I, the expression of which is regulated posttranscriptionally in hepatic stellate cells. The most potent stimulus for collagen I production is TGF-beta, which is derived from both paracrine and autocrine sources; TGF-beta also stimulates the production of other matrix components including cellular fibronectin and proteoglycans [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/15,155\">",
"     15,155",
"    </a>",
"    ]. Other factors that stimulate collagen I by activated stellate cells in culture include retinoids, angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/156\">",
"     156",
"    </a>",
"    ], interleukin-1b, tumor necrosis factor, and acetaldehyde. However, none of these is as potent as TGF-beta-1. The expression of type I collagen can be inhibited when protein factors responsible for increasing expression are blocked from binding to a conserved stem-loop in the 5' untranslated region of type I collagen mRNA, suggesting that this region is important in the regulation of collagen synthesis by stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/157\">",
"     157",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TGF-beta-1 stimulates collagen in stellate cells through a",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    and",
"    <span class=\"nowrap\">",
"     C/EBPb-dependent",
"    </span>",
"    mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/46\">",
"     46",
"    </a>",
"    ], which also involves Rho kinase [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/158\">",
"     158",
"    </a>",
"    ]. Signals downstream of TGF-beta include a family of bifunctional molecules known as SMADs, upon which many extracellular and intracellular signals converge to fine-tune and enhance the effects of TGF-beta during fibrogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/136\">",
"     136",
"    </a>",
"    ]. The response of SMADs in stellate cells differs between acute and chronic injury to further favor matrix production [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/159\">",
"     159",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, lipid peroxidation products are emerging as important stimuli to extracellular matrix production [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/160\">",
"     160",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Cellular sources of ECM in normal and fibrotic liver'",
"    </a>",
"    above.) Their effects may be amplified by loss of antioxidant capacity of stellate cells as they activate [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/161\">",
"     161",
"    </a>",
"    ]. These important insights have provided the rationale for the study of antioxidants in the treatment of a variety of liver diseases.",
"   </p>",
"   <p>",
"    Hepatic iron concentration may also influence fibrogenesis, at least in patients with hepatitis C. Hepatic iron stores in such patients correlated with histologic disease severity and with stellate cell numbers [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/162\">",
"     162",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Connective tissue growth factor",
"    <span class=\"nowrap\">",
"     (CTGF/CCN2)",
"    </span>",
"    is also a potent fibrogenic signal towards stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/163-166\">",
"     163-166",
"    </a>",
"    ] that is upregulated by hyperglycemia and hyperinsulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/167\">",
"     167",
"    </a>",
"    ]. Interestingly, TGF-beta stimulates CTGF primarily in hepatocytes, not stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/168,169\">",
"     168,169",
"    </a>",
"    ], a notable exception to the general rule that cytokine signaling in stellate cell activation is typically autocrine.",
"   </p>",
"   <p>",
"    Neurohumoral signaling contributes to stellate cell responses [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/170\">",
"     170",
"    </a>",
"    ]. Specifically cannabinoids are potent mediators of hepatic steatosis, stellate cell activation and fibrosis (reviewed in [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/171\">",
"     171",
"    </a>",
"    ]), as well as provoking the hemodynamic alterations associated with advanced liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/172\">",
"     172",
"    </a>",
"    ]. Two receptors, CB1 and CB2, exert opposing effects, with CB1 a fibrogenic pathway and CB2 antifibrotic. Thus, antagonism of CB1 signaling in stellate cells represents a promising antifibrotic strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/173\">",
"     173",
"    </a>",
"    ]. In addition, neurotrophin receptor signaling has emerged as a potential target based on its contributions to stellate cell activation and its regulation by thyroid hormone [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/174-176\">",
"     174-176",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, agonism of CB2 receptors, which are also expressed by stellate cells, reverses fibrosis in experimental animals [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/177\">",
"     177",
"    </a>",
"    ]. The fundamental challenge of developing cannabinoid therapeutics for liver disease is to minimize central nervous system effects, since CB1 and CB2 receptors are abundantly expressed in brain. Similarly, opioids signal in stellate cells and promote fibrogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/178,179\">",
"     178,179",
"    </a>",
"    ], which is antagonized by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    . Finally, sympathetic neurotransmitters also contribute to activation pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/180\">",
"     180",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leptin, a ubiquitous adipokine, is profibrogenic, and its levels are elevated in patients who are obese [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/181-183\">",
"     181-183",
"    </a>",
"    ]. In contrast, adiponectin is a natural counter-regulator to leptin whose activity is diminished in advanced liver diseases and obesity, raising the prospect that it may have therapeutic value as an antifibrotic [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/183-185\">",
"     183-185",
"    </a>",
"    ]. In addition, ghrelin, an orexigenic hormone, may attenuate hepatic fibrosis based on animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/186\">",
"     186",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Contractility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contractility of stellate cells may be a major determinant of early and late increases in portal resistance during liver fibrosis. The collagenous bands typical of end-stage cirrhosis contain large numbers of activated stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/187\">",
"     187",
"    </a>",
"    ]. These impede portal blood flow by constricting individual sinusoids and by contracting the cirrhotic liver. The acquisition of a contractile phenotype during stellate cell activation has been documented in culture and in vivo, and is mediated in part by receptors which interact with the extracellular matrix [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/136\">",
"     136",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the process of becoming contractile, stellate cells develop increased expression of the cytoskeletal protein alpha smooth muscle actin. If smooth muscle actin is required for contraction, then inactivating it could represent a therapeutic target for treating portal hypertension.",
"   </p>",
"   <p>",
"    The major stimulus for stellate cell contraction is endothelin-1, whose receptors are expressed on quiescent and activated stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/188\">",
"     188",
"    </a>",
"    ]. Endothelin activity is antagonized by the nuclear receptor FXR [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/189\">",
"     189",
"    </a>",
"    ]. With activation, receptor expression does not increase (unlike PDGF receptors) but there is a shift in the predominant type of endothelin receptor and increased sensitivity to autocrine endothelin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/187,190\">",
"     187,190",
"    </a>",
"    ]. Locally produced vasodilator substances (particularly nitric oxide) may counteract the constrictive effects of endothelin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/187\">",
"     187",
"    </a>",
"    ]. In vivo studies suggest that carbon monoxide also mediates sinusoidal relaxation through its effects on stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/191\">",
"     191",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Matrix degradation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, quantitative and qualitative changes in matrix protease activity have an important role in extracellular matrix remodeling accompanying fibrosing liver injury. Because stellate cells express virtually all the components required for pathologic matrix degradation, they have a key role not only in matrix production, but also matrix degradation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Retinoid loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activation of stellate cells is accompanied by the loss of the characteristic perinuclear retinoid (vitamin A) droplets. In culture, retinoid is stored as retinyl esters whereas the form of retinoid released outside the cell during activation is retinol, suggesting that there is intracellular hydrolysis of esters prior to export [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/61\">",
"     61",
"    </a>",
"    ]. Whether retinoid loss is required for stellate cells to activate, and which retinoids might accelerate or prevent activation is incompletely understood.",
"   </p>",
"   <p>",
"    Several nuclear retinoid receptors have been identified in stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/192\">",
"     192",
"    </a>",
"    ]. These molecules bind intracellular retinoid ligands and regulate gene expression, but it is uncertain whether they have a regulatory role in fibrogenesis. The question has important clinical implications since efforts are being made to use retinoids therapeutically.",
"   </p>",
"   <p>",
"    Peroxisome proliferator activated receptors (PPAR), in particular PPARg, have been identified in stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/193,194\">",
"     193,194",
"    </a>",
"    ]. Their expression decreases with activation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/193,194\">",
"     193,194",
"    </a>",
"    ]. Ligands for this newly identified nuclear receptor family downregulate stellate cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/194\">",
"     194",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The intracellular lipid storage protein, adipose differentiation related protein (ADRP), has been uncovered in stellate cells; its expression is reduced during cellular activation, and it is induced by retinoid exposure, suggesting that ADRP may have a regulatory role linking lipid content to cellular activation through an unknown mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/195\">",
"     195",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Inflammatory signaling and WBC chemoattraction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stellate cells are assuming an increasingly central role in our understanding of hepatic inflammation. They can amplify the inflammatory response by inducing infiltration of mono- and polymorphonuclear leukocytes. Activated stellate cells produce chemokines that include MCP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/196\">",
"     196",
"    </a>",
"    ], CCL21 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/197\">",
"     197",
"    </a>",
"    ], RANTES, and CCR5 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/198\">",
"     198",
"    </a>",
"    ], among several others [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/199-202\">",
"     199-202",
"    </a>",
"    ]. These molecules are particularly attractive therapeutic targets, in part because chemokine receptors are G-coupled protein receptors, which are especially targetable by antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/203\">",
"     203",
"    </a>",
"    ]. Stellate cells also express toll-like receptors (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/118\">",
"     118",
"    </a>",
"    ], indicating a capacity to interact with bacterial lipopolysaccharide, which in turn stimulates stellate cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/204,205\">",
"     204,205",
"    </a>",
"    ]. Stellate cells can also function as antigen presenting cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/206\">",
"     206",
"    </a>",
"    ] that can stimulate lymphocyte proliferation or apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/207\">",
"     207",
"    </a>",
"    ]. Stellate cells produce neutrophil chemoattractants, which could contribute to the neutrophil accumulation characteristic of alcoholic liver disease.",
"   </p>",
"   <p>",
"    In addition to regulating leukocyte behavior, stellate cells may in turn be affected by specific lymphocyte populations [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/208\">",
"     208",
"    </a>",
"    ]. As an example, CD8 cells harbor more fibrogenic activity towards stellate cells than CD4 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/70\">",
"     70",
"    </a>",
"    ], which may explain in part the increased hepatic fibrosis seen in patients with",
"    <span class=\"nowrap\">",
"     HCV/HIV",
"    </span>",
"    coinfection, where",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratios are reduced, that in patients mono-infected with HCV alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Links between stellate and progenitor cells, fibrosis, and cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that stellate cells express the stem cell marker CD133 raises the possibility that they are true progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/209-211\">",
"     209-211",
"    </a>",
"    ]. Importantly, the requirement for fibrosis to occur before HCC develops in patients with chronic HCV remains unexplained. Potential explanations have included the presence of secreted survival factors that prevent apoptosis of DNA-damaged hepatocytes and activated stellate cells (eg, Gas6 [",
"    <a class=\"abstract\" href=\"UTD.htm?32/30/33258/abstract/212\">",
"     212",
"    </a>",
"    ]), reduced tumor surveillance due to decreasing NK cell number and function,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the accelerated shortening of telomeres that accompanies progressive fibrosis. How fibrosis promotes HCC is an important, unanswered question.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5140737\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Extracellular matrix (ECM) refers to a group of macromolecules that comprise the scaffolding of normal and fibrotic liver. These include collagens, non-collagen glycoproteins, matrix-bound growth factors, glycosaminoglycans, proteoglycans, and matricellular proteins. A great deal of progress has been made in identifying new members of these families and in understanding how these molecules interact. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Extracellular matrix composition of the normal and fibrotic liver'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Matrix alterations observed during fibrogenesis alter cellular behavior by processes involving cell membrane receptors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Biologic activity of extracellular matrix'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A major advance in the understanding of hepatic fibrosis has been the identification of the cellular sources of ECM. The hepatic stellate cell (previously called the lipocyte, Ito, fat-storing, or perisinusoidal cell) is the primary source of ECM in normal and fibrotic liver. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cellular sources of ECM in normal and fibrotic liver'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fibrosis reflects a balance between matrix production and degradation. The degradation of extracellular matrix is a key event in hepatic fibrosis. Early disruption of the normal hepatic matrix by matrix proteases hastens its replacement by scar matrix, which has deleterious effects on cell function. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Degradation of extracellular matrix'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hepatic stellate cell activation is the common pathway leading to hepatic fibrosis. Once activated, hepatic stellate cells release chemokines and other leukocyte chemoattractants, while upregulating the expression of important inflammatory receptors such as ICAM-1, chemokine receptors, and mediators of lipopolysaccharide signaling. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Stellate cell activation, the central event in hepatic fibrosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/1\">",
"      Poynard T, Mathurin P, Lai CL, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/2\">",
"      Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 37:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/3\">",
"      Hillebrandt S, Goos C, Matern S, Lammert F. Genome-wide analysis of hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on chromosome 15. Gastroenterology 2002; 123:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/4\">",
"      Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010; 7:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/5\">",
"      Ismair MG, Stieger B, Cattori V, et al. Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 2001; 121:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/6\">",
"      Bonis PA, Friedman SL, Kaplan MM. Is liver fibrosis reversible? N Engl J Med 2001; 344:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/7\">",
"      Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/8\">",
"      Falize L, Guillygomarc'h A, Perrin M, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/9\">",
"      Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/10\">",
"      Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/11\">",
"      Roberts S, Gordon A, McLean C, et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 2007; 5:932.",
"     </a>",
"    </li>",
"    <li>",
"     Friedman SL. Hepatic Fibrosis: The consequences of liver disease. In: Schiff's Diseases of the Liver, 9th edition, Lippincott, Williams &amp; Wilkins, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/13\">",
"      Schuppan D, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001; 21:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/14\">",
"      Rojkind M, Giambrone MA, Biempica L. Collagen types in normal and cirrhotic liver. Gastroenterology 1979; 76:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/15\">",
"      Gressner AM. The cell biology of liver fibrogenesis - an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998; 292:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/16\">",
"      McGuire RF, Bissell DM, Boyles J, Roll FJ. Role of extracellular matrix in regulating fenestrations of sinusoidal endothelial cells isolated from normal rat liver. Hepatology 1992; 15:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/17\">",
"      Lee JS, Semela D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 2007; 45:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/18\">",
"      Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010; 30:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/19\">",
"      Dev A, Patel K, Conrad A, et al. Relationship of smoking and fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2006; 4:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/20\">",
"      Yang C, Zeisberg M, Mosterman B, et al. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology 2003; 124:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/21\">",
"      Zhou X, Murphy FR, Gehdu N, et al. Engagement of alphavbeta3 integrin regulates proliferation and apoptosis of hepatic stellate cells. J Biol Chem 2004; 279:23996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/22\">",
"      Melton AC, Soon RK Jr, Park JG, et al. Focal adhesion disassembly is an essential early event in hepatic stellate cell chemotaxis. Am J Physiol Gastrointest Liver Physiol 2007; 293:G1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/23\">",
"      Yee HF Jr. Rho directs activation-associated changes in rat hepatic stellate cell morphology via regulation of the actin cytoskeleton. Hepatology 1998; 28:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/24\">",
"      Choi SS, Sicklick JK, Ma Q, et al. Sustained activation of Rac1 in hepatic stellate cells promotes liver injury and fibrosis in mice. Hepatology 2006; 44:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/25\">",
"      Schuppan D, Schmid M, Somasundaram R, et al. Collagens in the liver extracellular matrix bind hepatocyte growth factor. Gastroenterology 1998; 114:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/26\">",
"      Wells RG. The role of matrix stiffness in regulating cell behavior. Hepatology 2008; 47:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/27\">",
"      Kazemi F, Kettaneh A, N'kontchou G, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006; 45:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/28\">",
"      Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007; 5:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/29\">",
"      Ruoslahti E, Engvall E. Integrins and vascular extracellular matrix assembly. J Clin Invest 1997; 99:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/30\">",
"      Patsenker E, Popov Y, Stickel F, et al. Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology 2008; 135:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/31\">",
"      Carloni V, Defranco RM, Caligiuri A, et al. Cell adhesion regulates platelet-derived growth factor-induced MAP kinase and PI-3 kinase activation in stellate cells. Hepatology 2002; 36:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/32\">",
"      Carloni V, Pinzani M, Giusti S, et al. Tyrosine phosphorylation of focal adhesion kinase by PDGF is dependent on ras in human hepatic stellate cells. Hepatology 2000; 31:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/33\">",
"      Couvelard A, Scoazec JY, Feldmann G. Expression of cell-cell and cell-matrix adhesion proteins by sinusoidal endothelial cells in the normal and cirrhotic human liver. Am J Pathol 1993; 143:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/34\">",
"      Friedman SL. Stellate cells: a moving target in hepatic fibrogenesis. Hepatology 2004; 40:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/35\">",
"      Racine-Samson L, Rockey DC, Bissell DM. The role of alpha1beta1 integrin in wound contraction. A quantitative analysis of liver myofibroblasts in vivo and in primary culture. J Biol Chem 1997; 272:30911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/36\">",
"      Adams DH, Hubscher SG, Fisher NC, et al. Expression of E-selectin and E-selectin ligands in human liver inflammation. Hepatology 1996; 24:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/37\">",
"      Adams DH, Burra P, Hubscher SG, et al. Endothelial activation and circulating vascular adhesion molecules in alcoholic liver disease. Hepatology 1994; 19:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/38\">",
"      Nakanuma Y, Yasoshima M, Tsuneyama K, Harada K. Histopathology of primary biliary cirrhosis with emphasis on expression of adhesion molecules. Semin Liver Dis 1997; 17:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/39\">",
"      Olaso E, Ikeda K, Eng FJ, et al. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. J Clin Invest 2001; 108:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/40\">",
"      Vlodavsky I, Miao HQ, Medalion B, et al. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibroblast growth factor. Cancer Metastasis Rev 1996; 15:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/41\">",
"      Inagaki Y, Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007; 56:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/42\">",
"      Breitkopf K, Godoy P, Ciuclan L, et al. TGF-beta/Smad signaling in the injured liver. Z Gastroenterol 2006; 44:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/43\">",
"      Liu C, Ga&ccedil;a MD, Swenson ES, et al. Smads 2 and 3 are differentially activated by transforming growth factor-beta (TGF-beta ) in quiescent and activated hepatic stellate cells. Constitutive nuclear localization of Smads in activated cells is TGF-beta-independent. J Biol Chem 2003; 278:11721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/44\">",
"      Uemura M, Swenson ES, Ga&ccedil;a MD, et al. Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell 2005; 16:4214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/45\">",
"      Wiercinska E, Wickert L, Denecke B, et al. Id1 is a critical mediator in TGF-beta-induced transdifferentiation of rat hepatic stellate cells. Hepatology 2006; 43:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/46\">",
"      Garc&iacute;a-Trevijano ER, Iraburu MJ, Fontana L, et al. Transforming growth factor beta1 induces the expression of alpha1(I) procollagen mRNA by a hydrogen peroxide-C/EBPbeta-dependent mechanism in rat hepatic stellate cells. Hepatology 1999; 29:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/47\">",
"      Dooley S, Delvoux B, Lahme B, et al. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000; 31:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/48\">",
"      Wells RG, Kruglov E, Dranoff JA. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett 2004; 559:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/49\">",
"      Kinnman N, Housset C. Peribiliary myofibroblasts in biliary type liver fibrosis. Front Biosci 2002; 7:d496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/50\">",
"      Kruglov EA, Jain D, Dranoff JA. Isolation of primary rat liver fibroblasts. J Investig Med 2002; 50:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/51\">",
"      Forbes SJ, Russo FP, Rey V, et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004; 126:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/52\">",
"      Kalluri R, Neilson EG. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003; 112:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/53\">",
"      Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008; 88:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/54\">",
"      Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000; 275:2247.",
"     </a>",
"    </li>",
"    <li>",
"     The Hepatic Stellate Cell, Friedman SL (Ed), Thieme, New York 2001. Vol Vol 21.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/56\">",
"      Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001; 21:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/57\">",
"      Bachem MG, Schneider E, Gross H, et al. Identification, culture, and characterization of pancreatic stellate cells in rats and humans. Gastroenterology 1998; 115:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/58\">",
"      Magness ST, Bataller R, Yang L, Brenner DA. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology 2004; 40:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/59\">",
"      Apte MV, Wilson JS. Mechanisms of pancreatic fibrosis. Dig Dis 2004; 22:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/60\">",
"      Bachem MG, Sch&uuml;nemann M, Ramadani M, et al. Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 2005; 128:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/61\">",
"      Friedman SL. Hepatic stellate cells. Prog Liver Dis 1996; 14:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/62\">",
"      Reeves HL, Burt AD, Wood S, Day CP. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996; 25:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/63\">",
"      Enzan H, Himeno H, Iwamura S, et al. Sequential changes in human Ito cells and their relation to postnecrotic liver fibrosis in massive and submassive hepatic necrosis. Virchows Arch 1995; 426:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/64\">",
"      Enzan H, Himeno H, Iwamura S, et al. Alpha-smooth muscle actin-positive perisinusoidal stromal cells in human hepatocellular carcinoma. Hepatology 1994; 19:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/65\">",
"      Schmitt-Gr&auml;ff A, Kr&uuml;ger S, Bochard F, et al. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol 1991; 138:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/66\">",
"      Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest 1990; 86:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/67\">",
"      Herbst H, Frey A, Heinrichs O, et al. Heterogeneity of liver cells expressing procollagen types I and IV in vivo. Histochem Cell Biol 1997; 107:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/68\">",
"      Roskams T, Moshage H, De Vos R, et al. Heparan sulfate proteoglycan expression in normal human liver. Hepatology 1995; 21:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/69\">",
"      Jarnagin WR, Rockey DC, Koteliansky VE, et al. Expression of variant fibronectins in wound healing: cellular source and biological activity of the EIIIA segment in rat hepatic fibrogenesis. J Cell Biol 1994; 127:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/70\">",
"      Safadi R, Ohta M, Alvarez CE, et al. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology 2004; 127:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/71\">",
"      El-Youssef M, Mu Y, Huang L, et al. Increased expression of transforming growth factor-beta1 and thrombospondin-1 in congenital hepatic fibrosis: possible role of the hepatic stellate cell. J Pediatr Gastroenterol Nutr 1999; 28:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/72\">",
"      Jhandier MN, Kruglov EA, Lavoie EG, et al. Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of NTPDase2. J Biol Chem 2005; 280:22986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/73\">",
"      Beaussier M, Wendum D, Schiffer E, et al. Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries. Lab Invest 2007; 87:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/74\">",
"      Kisseleva T, Uchinami H, Feirt N, et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006; 45:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/75\">",
"      Zeisberg M, Yang C, Martino M, et al. Fibroblasts derive from hepatocytes in liver fibrosis via epithelial to mesenchymal transition. J Biol Chem 2007; 282:23337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/76\">",
"      Kruglov EA, Nathanson RA, Nguyen T, Dranoff JA. Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. Am J Physiol Gastrointest Liver Physiol 2006; 290:G765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/77\">",
"      Dranoff JA, Ogawa M, Kruglov EA, et al. Expression of P2Y nucleotide receptors and ectonucleotidases in quiescent and activated rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2004; 287:G417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/78\">",
"      Benyon RC, Arthur MJ. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001; 21:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/79\">",
"      Arthur MJ, Stanley A, Iredale JP, et al. Secretion of 72 kDa type IV collagenase/gelatinase by cultured human lipocytes. Analysis of gene expression, protein synthesis and proteinase activity. Biochem J 1992; 287 ( Pt 3):701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/80\">",
"      Milani S, Herbst H, Schuppan D, et al. Differential expression of matrix-metalloproteinase-1 and -2 genes in normal and fibrotic human liver. Am J Pathol 1994; 144:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/81\">",
"      Vyas SK, Leyland H, Gentry J, Arthur MJ. Rat hepatic lipocytes synthesize and secrete transin (stromelysin) in early primary culture. Gastroenterology 1995; 109:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/82\">",
"      Th&eacute;ret N, Musso O, L'Helgoualc'h A, Cl&eacute;ment B. Activation of matrix metalloproteinase-2 from hepatic stellate cells requires interactions with hepatocytes. Am J Pathol 1997; 150:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/83\">",
"      Th&eacute;ret N, Lehti K, Musso O, Cl&eacute;ment B. MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells. Hepatology 1999; 30:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/84\">",
"      Benyon RC, Iredale JP, Goddard S, et al. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996; 110:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/85\">",
"      Arii S, Mise M, Harada T, et al. Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 1996; 24:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/86\">",
"      Milani S, Herbst H, Schuppan D, et al. Cellular sources of extracellular matrix proteins in normal and fibrotic liver. Studies of gene expression by in situ hybridization. J Hepatol 1995; 22:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/87\">",
"      Murawaki Y, Ikuta Y, Idobe Y, et al. Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol 1997; 26:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/88\">",
"      Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/89\">",
"      Herbst H, Wege T, Milani S, et al. Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis. Am J Pathol 1997; 150:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/90\">",
"      Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/91\">",
"      Trim JE, Samra SK, Arthur MJ, et al. Upstream tissue inhibitor of metalloproteinases-1 (TIMP-1) element-1, a novel and essential regulatory DNA motif in the human TIMP-1 gene promoter, directly interacts with a 30-kDa nuclear protein. J Biol Chem 2000; 275:6657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/92\">",
"      Issa R, Zhou X, Constandinou CM, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking. Gastroenterology 2004; 126:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/93\">",
"      Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol 2006; 44:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/94\">",
"      Bachem MG, Melchior R, Gressner AM. The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells. J Clin Chem Clin Biochem 1989; 27:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/95\">",
"      Fischer R, Cariers A, Reinehr R, H&auml;ussinger D. Caspase 9-dependent killing of hepatic stellate cells by activated Kupffer cells. Gastroenterology 2002; 123:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/96\">",
"      Canbay A, Higuchi H, Bronk SF, et al. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002; 123:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/97\">",
"      Mehal W, Imaeda A. Cell death and fibrogenesis. Semin Liver Dis 2010; 30:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/98\">",
"      Jaeschke H. Inflammation in response to hepatocellular apoptosis. Hepatology 2002; 35:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/99\">",
"      Watanabe A, Hashmi A, Gomes DA, et al. Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9. Hepatology 2007; 46:1509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/100\">",
"      Takehara T, Tatsumi T, Suzuki T, et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 2004; 127:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/101\">",
"      Pockros PJ, Schiff ER, Shiffman ML, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007; 46:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/102\">",
"      Taimr P, Higuchi H, Kocova E, et al. Activated stellate cells express the TRAIL receptor-2/death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003; 37:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/103\">",
"      Wright MC, Issa R, Smart DE, et al. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 2001; 121:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/104\">",
"      Anan A, Baskin-Bey ES, Bronk SF, et al. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 2006; 43:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/105\">",
"      Canbay A, Taimr P, Torok N, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003; 83:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/106\">",
"      Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/107\">",
"      Nieto N, Friedman SL, Cederbaum AI. Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells. J Biol Chem 2002; 277:9853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/108\">",
"      Nieto N, Friedman SL, Cederbaum AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology 2002; 35:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/109\">",
"      Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/110\">",
"      Jaeschke H. Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol 2006; 290:G1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/111\">",
"      Castillo T, Koop DR, Kamimura S, et al. Role of cytochrome P-450 2E1 in ethanol-, carbon tetrachloride- and iron-dependent microsomal lipid peroxidation. Hepatology 1992; 16:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/112\">",
"      Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001; 21:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/113\">",
"      De Minicis S, Brenner DA. NOX in liver fibrosis. Arch Biochem Biophys 2007; 462:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/114\">",
"      Lin W, Wu G, Li S, et al. HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem 2011; 286:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/115\">",
"      Lin W, Tsai WL, Shao RX, et al. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 2010; 138:2509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/116\">",
"      Nussler AK, Di Silvio M, Billiar TR, et al. Stimulation of the nitric oxide synthase pathway in human hepatocytes by cytokines and endotoxin. J Exp Med 1992; 176:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/117\">",
"      Venkatraman A, Shiva S, Wigley A, et al. The role of iNOS in alcohol-dependent hepatotoxicity and mitochondrial dysfunction in mice. Hepatology 2004; 40:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/118\">",
"      Paik YH, Schwabe RF, Bataller R, et al. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003; 37:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/119\">",
"      Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/120\">",
"      Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/121\">",
"      Cl&eacute;ment S, Pascarella S, Conzelmann S, et al. The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8. J Hepatol 2010; 52:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/122\">",
"      Bataller R, Paik YH, Lindquist JN, et al. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004; 126:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/123\">",
"      Schulze-Krebs A, Preimel D, Popov Y, et al. Hepatitis C virus-replicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 2005; 129:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/124\">",
"      Jin Z, Sun R, Wei H, et al. Accelerated liver fibrosis in hepatitis B virus transgenic mice: involvement of natural killer T cells. Hepatology 2011; 53:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/125\">",
"      Rippe RA, Brenner DA. From quiescence to activation: Gene regulation in hepatic stellate cells. Gastroenterology 2004; 127:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/126\">",
"      Mann J, Oakley F, Akiboye F, et al. Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. Cell Death Differ 2007; 14:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/127\">",
"      Tsukamoto H, She H, Hazra S, et al. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J Gastroenterol Hepatol 2006; 21 Suppl 3:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/128\">",
"      Gieling RG, Elsharkawy AM, Caama&ntilde;o JH, et al. The c-Rel subunit of nuclear factor-kappaB regulates murine liver inflammation, wound-healing, and hepatocyte proliferation. Hepatology 2010; 51:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/129\">",
"      Oakley F, Meso M, Iredale JP, et al. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 2005; 128:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/130\">",
"      Mann J, Chu DC, Maxwell A, et al. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology 2010; 138:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/131\">",
"      Stefanovic B, Hellerbrand C, Holcik M, et al. Posttranscriptional regulation of collagen alpha1(I) mRNA in hepatic stellate cells. Mol Cell Biol 1997; 17:5201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/132\">",
"      Stefanovic B, Hellerbrand C, Brenner DA. Regulatory role of the conserved stem-loop structure at the 5' end of collagen alpha1(I) mRNA. Mol Cell Biol 1999; 19:4334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/133\">",
"      Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci 2002; 7:d1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/134\">",
"      Wong L, Yamasaki G, Johnson RJ, Friedman SL. Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture. J Clin Invest 1994; 94:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/135\">",
"      Cao S, Yaqoob U, Das A, et al. Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin Invest 2010; 120:2379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/136\">",
"      Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001; 21:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/137\">",
"      Di Sario A, Bendia E, Taffetani S, et al. Selective Na+/H+ exchange inhibition by cariporide reduces liver fibrosis in the rat. Hepatology 2003; 37:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/138\">",
"      Campbell JS, Hughes SD, Gilbertson DG, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci U S A 2005; 102:3389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/139\">",
"      Yoshiji H, Kuriyama S, Yoshii J, et al. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003; 52:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/140\">",
"      Marra F, Grandaliano G, Valente AJ, Abboud HE. Thrombin stimulates proliferation of liver fat-storing cells and expression of monocyte chemotactic protein-1: potential role in liver injury. Hepatology 1995; 22:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/141\">",
"      Marra F, DeFranco R, Grappone C, et al. Expression of the thrombin receptor in human liver: up-regulation during acute and chronic injury. Hepatology 1998; 27:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/142\">",
"      Steiling H, M&uuml;hlbauer M, Bataille F, et al. Activated hepatic stellate cells express keratinocyte growth factor in chronic liver disease. Am J Pathol 2004; 165:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/143\">",
"      Kim SY, Cho BH, Kim UH. CD38-mediated Ca2+ signaling contributes to angiotensin II-induced activation of hepatic stellate cells: attenuation of hepatic fibrosis by CD38 ablation. J Biol Chem 2010; 285:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/144\">",
"      Czochra P, Klopcic B, Meyer E, et al. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 2006; 45:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/145\">",
"      Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, et al. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007; 46:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/146\">",
"      Maher JJ. Interactions between hepatic stellate cells and the immune system. Semin Liver Dis 2001; 21:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/147\">",
"      Marra F, DeFranco R, Grappone C, et al. Expression of monocyte chemotactic protein-1 precedes monocyte recruitment in a rat model of acute liver injury, and is modulated by vitamin E. J Investig Med 1999; 47:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/148\">",
"      Ikeda K, Wakahara T, Wang YQ, et al. In vitro migratory potential of rat quiescent hepatic stellate cells and its augmentation by cell activation. Hepatology 1999; 29:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/149\">",
"      Kinnman N, Hultcrantz R, Barbu V, et al. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest 2000; 80:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/150\">",
"      Marra F, Romanelli RG, Giannini C, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999; 29:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/151\">",
"      Bonacchi A, Romagnani P, Romanelli RG, et al. Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem 2001; 276:9945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/152\">",
"      Hashmi AZ, Hakim W, Kruglov EA, et al. Adenosine inhibits cytosolic calcium signals and chemotaxis in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2007; 292:G395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/153\">",
"      Friedman SL. Transcriptional regulation of stellate cell activation. J Gastroenterol Hepatol 2006; 21 Suppl 3:S79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/154\">",
"      Ruhl CE, Everhart JE. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005; 129:1928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/155\">",
"      George J, Wang SS, Sevcsik AM, et al. Transforming growth factor-beta initiates wound repair in rat liver through induction of the EIIIA-fibronectin splice isoform. Am J Pathol 2000; 156:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/156\">",
"      Bataller R, Schwabe RF, Choi YH, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003; 112:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/157\">",
"      Stefanovic B, Schnabl B, Brenner DA. Inhibition of collagen alpha 1(I) expression by the 5' stem-loop as a molecular decoy. J Biol Chem 2002; 277:18229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/158\">",
"      Shimada H, Staten NR, Rajagopalan LE. TGF-&beta;1 mediated activation of Rho kinase induces TGF-&beta;2 and endothelin-1 expression in human hepatic stellate cells. J Hepatol 2011; 54:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/159\">",
"      Tahashi Y, Matsuzaki K, Date M, et al. Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 2002; 35:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/160\">",
"      Svegliati Baroni G, D'Ambrosio L, Ferretti G, et al. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology 1998; 27:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/161\">",
"      Whalen R, Rockey DC, Friedman SL, Boyer TD. Activation of rat hepatic stellate cells leads to loss of glutathione S-transferases and their enzymatic activity against products of oxidative stress. Hepatology 1999; 30:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/162\">",
"      Rigamonti C, Andorno S, Maduli E, et al. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. Eur J Clin Invest 2002; 32 Suppl 1:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/163\">",
"      Paradis V, Dargere D, Bonvoust F, et al. Effects and regulation of connective tissue growth factor on hepatic stellate cells. Lab Invest 2002; 82:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/164\">",
"      Rachfal AW, Brigstock DR. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003; 26:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/165\">",
"      Gao R, Brigstock DR. Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J Biol Chem 2004; 279:8848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/166\">",
"      Chen L, Charrier AL, Leask A, et al. Ethanol-stimulated differentiated functions of human or mouse hepatic stellate cells are mediated by connective tissue growth factor. J Hepatol 2011; 55:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/167\">",
"      Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/168\">",
"      Weng HL, Ciuclan L, Liu Y, et al. Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes. Hepatology 2007; 46:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/169\">",
"      Gressner OA, Lahme B, Demirci I, et al. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007; 47:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/170\">",
"      Roskams T, Cassiman D, De Vos R, Libbrecht L. Neuroregulation of the neuroendocrine compartment of the liver. Anat Rec A Discov Mol Cell Evol Biol 2004; 280:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/171\">",
"      Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets 2007; 11:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/172\">",
"      B&aacute;tkai S, J&aacute;rai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/173\">",
"      Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/174\">",
"      Zvibel I, Atias D, Phillips A, et al. Thyroid hormones induce activation of rat hepatic stellate cells through increased expression of p75 neurotrophin receptor and direct activation of Rho. Lab Invest 2010; 90:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/175\">",
"      Kendall TJ, Hennedige S, Aucott RL, et al. p75 Neurotrophin receptor signaling regulates hepatic myofibroblast proliferation and apoptosis in recovery from rodent liver fibrosis. Hepatology 2009; 49:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/176\">",
"      Passino MA, Adams RA, Sikorski SL, Akassoglou K. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science 2007; 315:1853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/177\">",
"      Mu&ntilde;oz-Luque J, Ros J, Fern&aacute;ndez-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008; 324:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/178\">",
"      Ebrahimkhani MR, Kiani S, Oakley F, et al. Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats. Gut 2006; 55:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/179\">",
"      De Minicis S, Candelaresi C, Marzioni M, et al. Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo. Gut 2008; 57:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/180\">",
"      Oben JA, Roskams T, Yang S, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters. Gut 2004; 53:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/181\">",
"      Ikejima K, Okumura K, Kon K, et al. Role of adipocytokines in hepatic fibrogenesis. J Gastroenterol Hepatol 2007; 22 Suppl 1:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/182\">",
"      Choi SS, Syn WK, Karaca GF, et al. Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem 2010; 285:36551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/183\">",
"      Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/184\">",
"      Savvidou S, Hytiroglou P, Orfanou-Koumerkeridou H, et al. Low serum adiponectin levels are predictive of advanced hepatic fibrosis in patients with NAFLD. J Clin Gastroenterol 2009; 43:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/185\">",
"      Musso G, Gambino R, Biroli G, et al. Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic Beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2005; 100:2438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/186\">",
"      Moreno M, Chaves JF, Sancho-Bru P, et al. Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology 2010; 51:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/187\">",
"      Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001; 21:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/188\">",
"      Housset C, Rockey DC, Bissell DM. Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1. Proc Natl Acad Sci U S A 1993; 90:9266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/189\">",
"      Li J, Kuruba R, Wilson A, et al. Inhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand. PLoS One 2010; 5:e13955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/190\">",
"      Reinehr RM, Kubitz R, Peters-Regehr T, et al. Activation of rat hepatic stellate cells in culture is associated with increased sensitivity to endothelin 1. Hepatology 1998; 28:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/191\">",
"      Suematsu M, Goda N, Sano T, et al. Carbon monoxide: an endogenous modulator of sinusoidal tone in the perfused rat liver. J Clin Invest 1995; 96:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/192\">",
"      Ohata M, Lin M, Satre M, Tsukamoto H. Diminished retinoic acid signaling in hepatic stellate cells in cholestatic liver fibrosis. Am J Physiol 1997; 272:G589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/193\">",
"      Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000; 275:35715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/194\">",
"      Marra F, Efsen E, Romanelli RG, et al. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/195\">",
"      Lee TF, Mak KM, Rackovsky O, et al. Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (ADRP). J Cell Physiol 2010; 223:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/196\">",
"      Marra F, Pinzani M. Role of hepatic stellate cells in the pathogenesis of portal hypertension. Nefrologia 2002; 22 Suppl 5:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/197\">",
"      Bonacchi A, Petrai I, Defranco RM, et al. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 2003; 125:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/198\">",
"      Schwabe RF, Bataller R, Brenner DA. Human hepatic stellate cells express CCR5 and RANTES to induce proliferation and migration. Am J Physiol Gastrointest Liver Physiol 2003; 285:G949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/199\">",
"      Wasmuth HE, Lammert F, Zaldivar MM, et al. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 2009; 137:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/200\">",
"      Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010; 7:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/201\">",
"      Aoyama T, Inokuchi S, Brenner DA, Seki E. CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice. Hepatology 2010; 52:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/202\">",
"      Zaldivar MM, Pauels K, von Hundelshausen P, et al. CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology 2010; 51:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/203\">",
"      Berres ML, Koenen RR, Rueland A, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest 2010; 120:4129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/204\">",
"      Brun P, Castagliuolo I, Pinzani M, et al. Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2005; 289:G571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/205\">",
"      Pradere JP, Troeger JS, Dapito DH, et al. Toll-like receptor 4 and hepatic fibrogenesis. Semin Liver Dis 2010; 30:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/206\">",
"      Vi&ntilde;as O, Bataller R, Sancho-Bru P, et al. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 2003; 38:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/207\">",
"      Kobayashi S, Seki S, Kawada N, et al. Apoptosis of T cells in the hepatic fibrotic tissue of the rat: a possible inducing role of hepatic myofibroblast-like cells. Cell Tissue Res 2003; 311:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/208\">",
"      Zimmermann HW, Seidler S, Nattermann J, et al. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 2010; 5:e11049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/209\">",
"      Kordes C, Sawitza I, M&uuml;ller-Marbach A, et al. CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun 2007; 352:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/210\">",
"      Pintilie DG, Shupe TD, Oh SH, et al. Hepatic stellate cells' involvement in progenitor-mediated liver regeneration. Lab Invest 2010; 90:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/211\">",
"      Wang Y, Yao HL, Cui CB, et al. Paracrine signals from mesenchymal cell populations govern the expansion and differentiation of human hepatic stem cells to adult liver fates. Hepatology 2010; 52:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?32/30/33258/abstract/212\">",
"      Lafdil F, Chobert MN, Couchie D, et al. Induction of Gas6 protein in CCl4-induced rat liver injury and anti-apoptotic effect on hepatic stellate cells. Hepatology 2006; 44:228.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1233 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33258=[""].join("\n");
var outline_f32_30_33258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5140737\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTRACELLULAR MATRIX COMPOSITION OF THE NORMAL AND FIBROTIC LIVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BIOLOGIC ACTIVITY OF EXTRACELLULAR MATRIX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Integrins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other adhesion proteins and cell matrix receptors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Soluble growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CELLULAR SOURCES OF ECM IN NORMAL AND FIBROTIC LIVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DEGRADATION OF EXTRACELLULAR MATRIX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathologic matrix degradation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      STELLATE CELL ACTIVATION, THE CENTRAL EVENT IN HEPATIC FIBROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Initiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Gene regulation during stellate cell activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Perpetuation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Proliferation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chemotaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Fibrogenesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Contractility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Matrix degradation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Retinoid loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Inflammatory signaling and WBC chemoattraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Links between stellate and progenitor cells, fibrosis, and cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5140737\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1233\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1233|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/44/40647\" title=\"figure 1\">",
"      Sinusoidal events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/15/18677\" title=\"figure 2\">",
"      Stellate cell activation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/59/13242?source=related_link\">",
"      Emerging therapies for hepatic fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30650?source=related_link\">",
"      Noninvasive assessment of hepatic fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_30_33259="General approach to treatment of fatigue in palliative care";
var content_f32_30_33259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PALC%2F86231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PALC%2F86231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    General approach to treatment of fatigue in palliative care",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment of the underlying cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia - Red blood cell transfusion or an erythropoiesis stimulating agent, most useful in patients receiving chemotherapy who have severe anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deconditioning - exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression - antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections - antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dehydration - intravenous or subcutaneous fluids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoxia - oxygen,&nbsp;if hypoxemic (eg,&nbsp;oxygen saturation &lt;90 percent by pulse oximetry)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolic and endocrine disorders - correction of disorder (eg, thyroid or testosterone replacement)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insomnia - sleep hygiene, brief trial of short-acting hypnotics in refractory cases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain - NSAIDs, opioids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment of the symptom",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Established therapies - glucocorticoids, megestrol acetate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Less well established therapies - methylphenidate, modafinil, American Ginseng",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alternative therapies - melatonin, fish oil, yoga, and meditation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33259=[""].join("\n");
var outline_f32_30_33259=null;
var title_f32_30_33260="Irritant and allergic contact dermatitis";
var content_f32_30_33260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of irritant and allergic contact dermatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Irritant contact dermatitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Allergic contact dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Etiology",
"        </strong>",
"       </td>",
"       <td>",
"        Irritant substances",
"       </td>",
"       <td>",
"        Allergens",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Mechanisms",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Non-immunological",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Delayed-type hypersensitivity",
"        </p>",
"        <p>",
"         Antigen-specific T cells",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Sites",
"        </strong>",
"       </td>",
"       <td>",
"        Localized to the contact areas",
"       </td>",
"       <td>",
"        <p>",
"         At the site of the contact",
"        </p>",
"        <p>",
"         May be widespread",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Symptoms",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Burning, stinging, and pain",
"        </p>",
"        <p>",
"         Pruritus may be present",
"        </p>",
"       </td>",
"       <td>",
"        Pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Onset",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         May appear after first contact",
"        </p>",
"        <p>",
"         Usually minutes to hours (strong irritant) or 24 hours to one week (weak irritant)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Sensitization phase before onset",
"        </p>",
"        <p>",
"         Usually 24-72 hours after exposure",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Decrescendo phenomenon",
"        </strong>",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        <strong>",
"         Clinical manifestation",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Acute stage",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         Erythema, edema, vesicles, and bullae",
"        </p>",
"        <p>",
"         Necrosis and ulceration in severe cases",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Erythema, edema, vesicles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Chronic stage",
"       </td>",
"       <td class=\"sublist_other\">",
"        Fissuring, hyperkeratosis, and scaling",
"       </td>",
"       <td class=\"sublist_other\">",
"        Fissuring, hyperkeratosis, and scaling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Histopathology",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Mild spongiosis, necrosis of epidermal keratinocyte",
"        </p>",
"       </td>",
"       <td>",
"        Spongiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Patch testing",
"        </strong>",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Positive",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33260=[""].join("\n");
var outline_f32_30_33260=null;
var title_f32_30_33261="Risk wk for fetal abnormalities";
var content_f32_30_33261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Periods of sensitivity during development",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 267px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Unborn Patient: Prenatal Diagnosis and Treatment. Harrison, Golbus, Filly (eds). Philadelphia, Saunders, 1990. p. 44. Copyright &copy; 1990 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33261=[""].join("\n");
var outline_f32_30_33261=null;
var title_f32_30_33262="Pityriasis alba 1";
var content_f32_30_33262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pityriasis alba",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 263px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hypopigmented macules are present on the face of this young girl with pityriasis alba.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Nicole Sorensen, RN, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33262=[""].join("\n");
var outline_f32_30_33262=null;
var title_f32_30_33263="Antrum and pylorus";
var content_f32_30_33263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Antrum and pylorus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 181px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic views of the antrum (left) and pylorus (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_30_33263=[""].join("\n");
var outline_f32_30_33263=null;
